Infections in lung and heart transplant recipients : studies on the impact of bronchoscopy in the diagnosis of respiratory infections and detection of viral infections in blood and bronchoalveolar lavage fluid by Lehto, Juho
Department of Medicine, Division of Respiratory Diseases, Helsinki University Central Hospital 
and 





INFECTIONS IN LUNG AND HEART TRANSPLANT RECIPIENTS 
- Studies on the impact of bronchoscopy in the diagnosis of respiratory infections and 











To be publicly discussed with the permission of the Faculty of Medicine, University of Helsinki,  








Docent Maija Halme 
Department of Medicine, Division of Respiratory Diseases, 




Docent Petri K. Koskinen 
Transplantation laboratory;  
and Department of Medicine, Division of Nephrology, 







Professor Timo Paavonen 
Department of Medicine, Division of Pathology, 




Docent Hannu Jalanko 
Hospital for Children and Adolescents, 







Docent Heikki Mäkisalo 
Department of Transplantation and Liver Surgery,  








ISBN 978-952-92-1376-4 (paperback) 









































  Wisdom is the principal thing, therefore get wisdom; 
  and with all thy getting, get understanding. 
 













TABLE OF CONTENTS                        
 
                          Page 
 
LIST OF ORGINAL PUBLICATIONS       6 
 
ABBREVIATIONS        7 
 
ABSTRACT         9 
 
INTRODUCTION      11 
 
REVIEW OF THE LITERATURE     13 
 
1. Lung and heart transplantation     13 
    1.1. Indications and outcome     13 
    1.2. Immunosuppressive therapy     15 
    1.3. Infectious complications     17 
    1.4. Noninfectious complications     20 
2. Bronchoscopy in transplant recipients     22 
    2.1. Bronchoscopic techniques     22 
    2.2. Microbes demonstrated in bronchoscopic specimens   23 
    2.3. Bronchoscopy in lung transplant recipients    26 
    2.4. Bronchoscopy in other solid organ transplant recipients   27 
    2.5. Complications of the bronchoscopy    28 
3. Cytomegalovirus (CMV) infection in lung and heart transplant recipients  29 
    3.1. CMV       29 
    3.2. Definition and diagnosis of CMV infection    30 
    3.3. Risk factors and impact of CMV infection    32 
    3.4. Prevention and treatment of CMV infection    35 
4. Human herpesvirus(HHV)-6 and HHV-7 in transplant recipients   37 
    4.1. HHV-6 and HHV-7      37 
    4.2. Impact of HHV-6 and HHV-7     37 
    4.3. Prevention and treatment of HHV-6 and HHV-7   39 
 
AIMS OF THE STUDY      40 
 
MATERIALS AND METHODS     41 
 
1. Patients       41 
    1.1. Bronchoscopies performed on heart and lung transplant recipients (I, II)  43 
    1.2. Lung and heart transplant recipients monitored by CMV antigenemia,  
           DNAemia, and mRNAemia tests (III)    43 
    1.3. Lung transplant recipients monitored for CMV, HHV-6, and HHV-7 (IV)  44 
2. Bronchoscopies      45 
    2.1. The bronchoscopic procedures     45 
    2.2. Specimens received by the bronchoscopy    45 
    2.3. Significance of the findings received by the bronchoscopy   46 
3. CMV infection      47 
    3.1. Demonstration of CMV     47 
    3.2. Diagnosis of CMV infection     48 
    3.3. Prevention and treatment of CMV infection    48 
 
4. Demonstration of HHV-6 and HHV-7 (IV)    50 
5. Statistical analyses       51 
 
RESULTS       52 
 
1. Utility of bronchoscopies (I, II)     52 
2. Diagnoses established by the bronchoscopy (I, II)    53 
3. Safety of the bronchoscopies (I, II)     55 
4. CMV antigenemia, DNAemia, and mRNAemia in lung and heart transplant recipients (III) 56 
5. Usefulness of CMV DNAemia and mRNAemia tests in guiding antiviral therapy (III) 56 
6. HHV-6 and HHV-7 activation in lung transplant recipients (IV)   58 
7. Efficacy of the antiviral prophylaxis against CMV, HHV-6, and HHV-7 
    antigenemia (III, IV)      59 
 
DISCUSSION      61 
 
1. Usefulness of bronchoscopy     61 
2. Significance of microbes retrieved by bronchoscopy   63 
3. CMV DNAemia and mRNAemia and their relationship to antigenemia  65 
4. HHV-6 and HHV-7 antigenemia in lung transplant recipients   67 
5. Antiviral strategies against CMV, HHV-6, and HHV-7   69 
 
CONCLUSIONS      72 
 
YHTEENVETO (FINNISH SUMMARY)    73 
 
ACKNOWLEDGEMENTS     76 
 
REFERENCES      78 
 























LIST OF ORGINAL PUBLICATIONS 
 




I Lehto JT, Anttila V-J, Lommi J, Nieminen MS, Harjula A, Taskinen E, Tukiainen P, Halme 
M. Clinical usefulness of bronchoalveolar lavage in heart transplant recipients with 




II Lehto JT, Koskinen PK, Anttila V-J, Lautenschlager I, Lemström K, Sipponen J, Tukiainen 
P, Halme M. Bronchoscopy in the diagnosis and surveillance of respiratory infections in 
lung and heart-lung transplant recipients. Transplant International 2005;18:562-571. 
 
 
III Lehto JT, Lemström K, Halme M, Lappalainen M, Lommi J, Sipponen J, Harjula A, 
Tukiainen P, Koskinen PK. A prospective study comparing cytomegalovirus antigenemia, 
DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant 
recipients. Transplant International 2005;18:1318-1327. 
 
 
IV Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I. Human 
herpesvirus-6 and -7 after lung and heart-lung transplantation. The Journal of Heart and 


























ATG  Antithymocyte globulin 
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Infection is a major cause of mortality and morbidity after thoracic organ transplantation. The 
microbiological aetiology of the infections is broad necessitating accurate diagnostic evaluation. 
The aim of the present study was to evaluate the infectious complications after lung and heart 
transplantation, with a special emphasis on the usefulness of bronchoscopy and the demonstration 
of cytomegalovirus (CMV), human herpes virus (HHV)-6, and HHV-7.  
 
We reviewed the diagnoses established from the specimens of all consecutive bronchoscopies 
performed on heart transplant recipients from May 1988 to December 2001 (n = 44) and lung 
transplant recipients from February 1994 to November 2002 (n = 472). To compare different assays 
in the detection of CMV and guiding the antiviral therapy, a total of 21 thoracic organ transplant 
recipients were prospectively monitored by CMV pp65-antigenemia, DNAemia (PCR), and 
mRNAemia (NASBA) tests. The antigenemia test was the reference assay for therapeutic 
intervention. In addition to CMV antigenemia, 22 lung transplant recipients were monitored for 
HHV-6 and HHV-7 antigenemia. 
 
The overall diagnostic yield of the clinically indicated bronchoscopies was 41 % in the heart 
transplant recipients and 61 % in the lung transplant recipients. The utility of the bronchoscopy was 
highest from one to six months after transplantation. In contrast, the findings from the surveillance 
bronchoscopies performed on lung transplant recipients led to a change in the previous treatment in 
only 6 % of the cases. Pneumocystis carinii and CMV were the most commonly detected pathogens 
in the bronchoscopic specimens. Furthermore, 15 (65 %) of the P. carinii infections in the lung 
transplant recipients were detected during adequate chemoprophylaxis. Although some 
complications of the bronchoscopy were detected, none of them were fatal.  
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 Antigenemia, DNAemia, and mRNAemia were present in 98 %, 72 %, and 43 % of the CMV 
infections detected in the study population, respectively. The optimal DNAemia cut-off levels 
(sensitivity/specificity) were 400 (75.9/92.7 %), 850 (91.3/91.3 %), and 1250 (100/91.5 %) 
copies/ml for the antigenemia of 2, 5, and 10 pp65-positive leukocytes/50 000 leukocytes, 
respectively. The sensitivities of the NASBA were 25.9, 43.5, and 56.3 % in detecting the same cut-
off levels of antigenemia. In general, CMV DNAemia was detected in 93 % and mRNAemia in 61 
% of the CMV antigenemias requiring antiviral therapy. HHV-6, HHV-7, and CMV antigenemia 
was detected in 20 (91 %), 11 (50 %), and 12 (55 %) of the 22 recipients (median 16, 31, and 165 
days) after lung transplantation, respectively. HHV-6 antigenemia occurred in 15 (79 %) and HHV-
7 antigenemia in seven (37 %) of these patients during ganciclovir or valganciclovir prophylaxis, 
while 11/12 of the CMV antigenemias were delayed beyond the cessation of prophylaxis. One case 
of pneumonitis and another of encephalitis were associated with HHV-6, but no other clinical 
manifestations could be linked to HHV-6 or HHV-7.  
 
The results of the present study indicate that bronchoscopy is a safe and useful diagnostic tool in 
lung and heart transplant recipients with a suspected respiratory infection, but the role of 
surveillance bronchoscopy in lung transplant recipients remains controversial. The Cobas PCR 
assay acts comparably with the antigenemia test in guiding the pre-emptive therapy against CMV 
when threshold levels of over 5 pp65-antigen positive leukocytes are used. In contrast, the low 
sensitivity of NASBA limits its usefulness in the guidance of the pre-emptive therapy. HHV-6 and 
HHV-7 activation is common after lung transplantation, but immediate clinical manifestations are 
infrequently linked to them. Antiviral prophylaxis against CMV is not able to prevent the 
appearance of HHV-6 and HHV-7 antigenemia. Future studies are needed to evaluate the overall 
efficacy of the surveillance bronchoscopies and preventive antiviral strategies on CMV, HHV-6, 





The first successful lung transplantation (LTx) was performed by James Hardy in 1963 and the first 
heart transplantation (HTx) by Christian Barnard in 1967 (Hardy et al. 1963, Barnard et al. 1967). 
The early results were poor, and it was not until the 1980’s by the discovery of cyclosporine (CyA) 
when lung, heart, and heart-lung transplantation (HLTx) gained a widespread acceptance as a 
therapeutic option. Today transplantation (Tx) offers markedly improved quality and longer 
expectancy of life for patients suffering from end-stage heart or lung disease (Arcasoy and Kotloff 
1999). Approximately 1800 lung and 3000 heart transplants are reported annually to the registry of 
the International Society for Heart and Lung Transplantation (ISHLT) (Taylor et al. 2006, Trulock 
et al. 2006). Despite the improvement on the outcomes, important postoperative complications still 
lower the five-year survival rate of lung transplant recipients (LTRs) and heart transplant recipients 
(HTRs), being approximately 49 % and 68 %, respectively (Taylor et al. 2006, Trulock et al. 2006).  
 
Infection is a major complication of LTx and HTx limiting the survival of the recipients during the 
first postoperative year (Speich and van der Bij 2001, Taylor et al. 2006, Trulock et al. 2006). This 
is mainly due to the immunosuppressive therapy impairing the host defenses but, to some extent, 
also to the continuous exposition of the allograft to the external environment in LTRs. The 
aetiology of the infections in transplant recipients is broad and differs from that of the general 
population, which makes the empiric therapy without a definite diagnosis difficult and hazardous. 
Thus, accurate diagnostic evaluation, when an infectious complication is suspected, is of great 
importance. The most common site of infection in both LTRs and HTRs is the respiratory tract, and 
diagnostic bronchoscopy is recommended as the initial invasive procedure in order to achieve 
specimens for microbiological investigations (Speich and van der Bij 2001, Miller et al. 1994, 
Nusair and Kramer 1999). However, only very few studies on the diagnostic usefulness of 
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bronchoscopy in HTRs exist, and the role of bronchoscopy in the surveillance of infections and 
other postoperative complications in asymptomatic LTRs is a matter of debate (Schulman et al. 
1988, Valentine et al. 2002). 
 
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality in thoracic organ 
transplant recipients despite advances in the development of antiviral agents (Rubin 2000, Zamora 
2004a). In addition to the short-term morbidity and mortality of the CMV infection itself, activation 
of the virus is also associated with chronic allograft injury (Zamora 2004a, Valantine 2004). A 
convenient, reliable, and rapid test is needed to detect the CMV infection. It would guide the use of 
antiviral agents and thereby prevent the complications of CMV in transplant recipients. CMV 
belongs to the beta-herpesvirus family, together with human herpesvirus-6 (HHV-6) first isolated in 
1986 and human herpesvirus-7 (HHV-7) found in 1990 (Salahuddin et al. 1986, Frenkel et al. 
1990). After primary infection during early childhood, HHV-6 and HHV-7, as other herpesviruses, 
can establish a latent infection for lifetime and reactivate during immunosuppression. Despite the 
increasing number of studies detecting HHV-6 and HHV-7 in transplant recipients, the clinical 
significance of these viruses is poorly understood and LTRs are included only in very few studies 
(Emery 2001, Jacobs et al. 2003). 
 
The present thesis was designed to study the diagnostics of infectious complications after LTx and 
HTx with a special emphasis on the usefulness of bronchoscopy and the demonstration of CMV, 







REVIEW OF THE LITERATURE 
 
1. Lung and heart transplantation 
 
1.1. Indications and outcome 
 
Transplantation for the end-stage lung or heart disease is generally considered when a patient 
suffers from severe symptoms limiting daily living activities (New York Heart Association class III 
or IV) despite all optimal medical therapy available, and the survival is expected to be less than 2-3 
years. The severity of the heart or lung disease has to meet the established criteria for Tx, but the 
functional status of the patient has to be good enough to allow successful LTx or HTx (Costanzo et 
al. 1995, Massad 2004, Orens et al. 2006). In addition, contraindications for thoracic organ Tx, such 
as active malignancies, serious dysfunction of other organs (e.g. kidney, liver, heart, and lung), 
active and uncontrolled infection, progressive neuromuscular disease, unresolved psychosocial 
problems, smoking (LTx) or other substance abuse should not be present (Massad 2004, Orens et al. 
2006). Heart-lung transplantation may be offered to patients with a congenital heart disease and 
end-stage lung disease which cannot be otherwise cured (Trulock 1997). The indications for LTx, 




















           
      Data from the registry of the ISHLT (www.ishlt.org/registries) and from Helsinki University Central Hospital; 






Actuarial survivals after LTx and HTx are shown in Figure 1. The long-term survival after LTx is 
shorter compared to the results of HTx and other solid organ transplantation (SOT). The high 
occurrence of rejection and infection in LTRs is probably the main factor responsible for the earlier 
allograft injury after LTx (Studer et al. 2003). However, the survival rate of LTRs operated after the 
mid-1990’s has improved compared to that of the earlier years of LTx (Trulock et al. 2006). 
Approximately 85 to 90 % of the survivors have no activity limitations five years after LTx and 
HTx, and the recipients report improved and acceptable quality-of-life after Tx (Vermeulen et al. 







             Lung (%)               Heart (%) Heart-lung (%) 
  Diagnosis     ISHLT      Finland    ISHLT     Finland ISHLT       Finland 
    
  COPD / Emphysema 38  14   4 7  
  Idiopathic pulmonary fibrosis 19  25   3 3  
  Cystic fibrosis 16  4   16         - 
  α1-antitrypsin deficiency  8  30   2         - 
  Primary pulmonary hypertension  4  10   24 40 
  Bronchiectasis  3   3   1  
  Sarcoidosis  3           -    1         - 
  Re-transplantation  2   3  2  0.3  2         - 
  Lymphangioleiomyomatosis  1   5      
  Congenital heart disease  1   3  2  2  32 40 
  Cardiomyopathy   46  56    
  Coronary artery disease   42  33    
  Valvular heart disease   3  5    
  Acquired heart disease     4 10 
  Other  5   4  5  4  10         - 
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Figure 1. Acturial survival after lung (A) and heart (B) transplantation (www.ishlt.org/registries). 
 
 
1.2. Immunosuppressive therapy 
 
 Life-long medication is mandatory for transplant recipients in order to suppress the host 
alloimmune responses against the donor organ and thereby to prevent rejection of the allograft. In 
the vast majority of LTRs and HTRs this immunosuppressive therapy consists of calcineurin 
inhibitor (cyclosporine A (CyA) or tacrolimus (Tac)), purine synthesis inhibitor (azathioprine 
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al. 2006). Calcineurin inhibitors suppress T-lymphocyte activation and proliferation by blocking the 
interleukin(IL)-2 gene transcription, AZA and MMF inhibit T and B lymphocyte proliferation by 
interfering the purine synthesis, and Cs have multiple anti-inflammatory effects mediated through 
the inhibition of RNA, DNA, and protein synthesis (Knoop et al. 2003, Lindenfeld et al. 2004). 
Sirolimus and its derivative everolimus are new immunosuppressive drugs, which may offer some 
advances to HTRs and LTRs (e.g. antiproliferative effects on chronic allograft injury), but their 
overall usefulness is not yet clear (Mancini et al. 2003, Knoop et al. 2003). In addition to the 
maintenance immunosuppression, approximately 40-50 % of thoracic organ transplant recipients 
receive perioperative induction therapy with anti-lymphocyte/thymocyte globulin or IL-2-receptor 
antibodies (Taylor et al. 2006, Trulock et al. 2006). The immunosuppressive drug-combinations 
used in HTRs and LTRs are listed in Table 2. 
 
 













                     
                   Data modified from the registry of the International Society for Heart and Lung  
                   Transplantation (ISHLT) (www.ishlt.org/registries). 
                   a All of the LTRs and 77 % of the HTRs reported in the ISHLT registry received  
                   corticosteroids together with other immunosuppressive drugs. 
                LTRs, lung transplant recipients; HTRs, heart transplant recipients;  





   
             Drugs a   LTRs (%)  HTRs (%) 
   
   Tacrolimus + MMF 33 33 
   Tacrolimus + AZA 20 2 
   Cyclosporine + MMF 13 38 
   Cyclosporine + AZA 12 4 
   Cyclosporine/Tacrolimus + SIR  6 7 
   Tacrolimus  9 4 
   Cyclosporine  - 3 
   Other  9 8 
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1.3. Infectious complications 
 
Due to the long-term immunosuppressive therapy, transplant recipients are vulnerable to many 
opportunistic and community-acquired pathogens. Microbes of which the key host defence is 
mediated by T-lymphocytes are of special importance (e.g. herpesviruses and Pneumocystis 
carinii). Infections are the most common cause of mortality during the first postoperative year after 
thoracic organ Tx and affect significantly the outcome of the recipients also thereafter (Taylor et al. 
2006, Trulock et al. 2006). Furthermore, the infectious complications in LTRs are more common 
than in any other SOT recipients and occur twice as frequently as in HTRs (Dummer et al. 1986, 
Kramer et al. 1993, van der Bij and Speich 2003). In addition to immunosuppressive therapy, 
factors predisposing LTRs to infectious complications include: 1) an allograft exposed continuously 
to the environment; 2) impaired mucociliary clearance; 3) interrupted lymphatic drainage; 4) 
denervation of the allograft with diminished cough reflex; 5) damage to bronchial epithelium and  
6) burden of microbes from the upper airways, paranasal sinuses, donor lungs or the remaining 
native lung in single lung Tx (van der Bij and Speich 2003). Over 70 % of the infections in LTRs 
involve the respiratory tract, and the lungs are the most common site of infection also in HTRs 
(Maurer et al. 1992, Horvath et al. 1993, Miller et al. 1994). 
 
There exists a typical sequence according to which different microbes cause infections after SOT 
(Fishman and Rubin 1998). The appearance of the most significant pathogens in HTRs and LTRs is 
presented in Figure 2. The first month after Tx is influenced predominantly by the infections related 
to prior surgery and intensive care. The time-period from one to six postoperative months is 
characterised by a high level of immunosuppression, and, therefore, by the emergence of many 
opportunistic pathogens. Although the infections beyond six months are increasingly community-
acquired, opportunistic pathogens are still detected especially when increased epidemiologic 
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exposure, an augmented level of immunosuppression or discontinuation of former prophylaxis are 
present (Villacian and Paya 1999, Speich and van der Bij 2001). 
 
Bacterial pneumonia is the most common infection after thoracic organ Tx and accounts for the 
majority of infection-related deaths in LTRs (Miller et al. 1994, Kramer et al. 1993). The most 
common causative bacteria in LTRs include Pseudomonas aeruginosa, Staphylococcus aureus, 
enterobacteriaceae, Enterococcus sp., and Haemophilus influenzae (Kramer et al. 1993, Chan et al. 
1996). Other significant bacterial infections include septichaemia related to vascular catheters and 
























Figure 2. Appearance of the most significant infections after thoracic organ transplantation. Bars 
indicate the common period for the onset of infection. Dotted lines show the continued risk of 
infection. Weight of the bars and lines indicate the significance of infection during different time 




The major importance of CMV after LTx and HTx is discussed in Section 3. Herpes simplex virus 
(HSV) may cause serious infections in HTR or LTR, but prophylaxis with acyclovir or ganciclovir 
is effective in preventing HSV (Smyth et al. 1990). The clinical significance of Ebstain-Barr virus 
(EBV) in transplant recipients is primarily related to its involvement in the development of the post-
transplant lymphoproliferative disorder (PTLD) (Gray et al. 1995, Paya et al. 1999). Although the 
overall role of respiratory viruses, such as respiratory syncytial virus (RSV), influenza, 
parainfluenza, and adenovirus, in transplant recipients is not known, they may cause serious lower 
respiratory tract infection in LTRs (Palmer et al. 1998a). 
 
Invasive aspergillosis (usually caused by A. fumigatus) is a life-threatening infection with a 
mortality rate of over 60 % among SOT recipients (Singh 2000). LTRs are extremely prone to this 
complication with reported incidences of 12 - 16 % (Yeldandi et al. 1995, Mehrad et al. 2001 
Nunley et al. 2002). Therefore, prophylactic or pre-emptive antifungal therapy is commonly used 
during the first postoperative months after LTx (Dummer et al. 2004). Candida species are 
responsible for many serious infections (e.g. sepsis) in transplant recipients, but involvement of the 
lung is rare with the exception of anastomotic infections reported in LTRs (Palmer et al. 1998b).  
 
Before the era of chemoprophylaxis, pneumonia caused by P. carinii (nowadays named as 
Pneumocystis jiroveci) was reported even in up to 40 and 88 % of the HTRs and LTRs, respectively 
(Gryzan et al. 1988, Olsen et al. 1993). The widely used and highly effective chemoprophylaxis has 
significantly decreased the role of this organism, but cases of P. carinii pneumonia (PCP) are 
reported after discontinuation of the prophylaxis and rarely also during the chemoprophylaxis 





1.4. Noninfectious complications  
 
Acute graft failure is the most common cause of death during the immediate postoperative period, 
after which acute rejection and infection are the most important complications during the first year 
after LTx and HTx. The diagnosis of acute rejection in LTRs is characterized by perivascular 
mononuclear infiltrates with or without accompanying lymphocytic bronchitis or bronchiolitis. 
Acute rejection is graded by the ISHLT Lung Rejection Study Group from minimal A1 (infrequent 
perivascular infiltrates) to severe A4 (diffuse perivascular, interstitial, and alveolar infiltrates). 
Similarly, the lymphocytic bronchitis is graded from minimal B1 (rare mononuclear cells in the 
submucosa) to severe B4 (dense infiltrate of mononuclear cells with dissociation of epithelium from 
the basement membrane) (Yousem et al. 1996). The definitions and grading system for acute 
rejection in HTRs has also been published under the direction of the ISHLT (Stewart et al. 2005).  
 
The major cause of late graft failure and the main limitation to the long-term survival of the 
recipients is chronic allograft dysfunction (Taylor et al. 2006 Trulock et al. 2006). Its manifestation 
is cardiac allograft vasculopathy (CAV) in HTRs and bronchiolitis obliterans syndrome (BOS) in 
LTRs. BOS is defined as persistent airflow obstruction demonstrated by spirometry in the absence 
of other conditions affecting the graft function (Estenne et al. 2002). Typical findings (e.g. air 
trapping) on high-resolution computed tomography (HRCT) supports the diagnosis of BOS 
(Bankier et al. 2001, Estenne et al. 2002). Obliterative bronchiolitis (OB) is the histological 
diagnosis of the condition. It is defined as peribronchial inflammation and obliteration of small and 
medium-sized bronchioli (Yousem et al. 1996). Characteristic features of CAV are intimal 
thickening and stenosis of the minor and major coronary arteries, which is clinically demonstrated 
by coronary angiography or intravascular ultrasound (Billingham 1992, Yeung et al. 1995, 





























































HTRs from CAV five years after transplantation (Boehler et al. 2003, Taylor et al. 2006). Although 
acute rejection is the best-documented risk factor for BOS and CAV, also infections (e.g. viruses) 
are associated with the development of chronic allograft injury (Sharples et al. 2002, Valantine 
2004, Taylor et al. 2006). BOS, in turn, pre-disposes the lung allograft to recurrent and resistant 
infections (e.g. Pseudomonas bronchitis and pneumonia) (Kramer et al. 1993, Reichenspurner et al. 
1996, van der Bij and Speich 2003). Long-term immunosuppressive medication also places 
transplant recipients at risk of cancer, especially lymphomas (PTLD) and skin malignancies. The 


































Figure 3. The most common causes of death after lung (A) and heart (B) transplantation. 
Data modified from the registry of ISHLT (www.ishlt.org/registries).  
OB, obliterative bronchiolitis; CAV, cardiac allograft vasculopathy. NOTE: Most of the graft failures occurring 




























































HTRs from CAV five years after transplantation (Boehler et al. 2003, Taylor et al. 2006). Although 
acute rejection is the best-documented risk factor for BOS and CAV, also infections (e.g. viruses) 
are associated with the development of chronic allograft injury (Sharples et al. 2002, Valantine 
2004, Taylor et al. 2006). BOS, in turn, pre-disposes the lung allograft to recurrent and resistant 
infections (e.g. Pseudomonas bronchitis and pneumonia) (Kramer et al. 1993, Reichenspurner et al. 
1996, van der Bij and Speich 2003). Long-term immunosuppressive medication also places 
transplant recipients at risk of cancer, especially lymphomas (PTLD) and skin malignancies. The 


































Figure 3. The most common causes of death after lung (A) and heart (B) transplantation. 
Data modified from the registry of ISHLT (www.ishlt.org/registries).  
OB, obliterative bronchiolitis; CAV, cardiac allograft vasculopathy. NOTE: Most of the graft failures occurring 
after the first year after transplantation are highly suggestive of being due to OB or CAV.  
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2. Bronchoscopy in transplant recipients 
 
The aetiology of pneumonia in transplant recipients differs from that in the general population, and 
the manifestations of respiratory infections are variably modified by the immunosuppressive 
therapy. Respiratory symptoms, fever, and radiographic infiltrates may also be due to non-
infectious complications such as malignancy, pulmonary oedema, anastomotic complications 
(LTRs) or acute rejection (LTRs). Thus, the definite diagnosis is of major importance in choosing 
adequate therapy for a transplant recipient with a suspected respiratory infection, and bronchoscopy 
is widely recommended as the initial invasive procedure in this clinical context (Nusair and Kramer 
1999, Speich and van der Bij 2001). 
 
2.1. Bronchoscopic techniques 
 
Bronchoscopy allows visualisation of the whole tracheobronchial tree providing a method to obtain 
samples from the lower respiratory tract. In order to receive samples without contamination from 
the upper airway secretions bronchial brushings with a protected specimen brush (PSB) may be 
used. The brush is inside a special single lumen or double lumen catheter when passed through the 
working channel of the flexible bronchoscope into a small bronchus where the actual brushing takes 
place (Wimberley et al. 1979). 
 
Bronchoalveolar lavage (BAL) is the most commonly used method to receive samples for 
microbiological studies. The bronchoscope is wedged to a small segmental or subsegmental 
bronchus, a fairly large volume (usually 100-240 ml) of saline is installed, and the BAL fluid 
(BALF) representing specimen from the alveolarlevel is retrieved by low pressure suction 
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infectious complications such as malignancy, pulmonary oedema, anastomotic complications 
(LTRs) or acute rejection (LTRs). Thus, the definite diagnosis is of major importance in choosing 
adequate therapy for a transplant recipient with a suspected respiratory infection, and bronchoscopy 
is widely recommended as the initial invasive procedure in this clinical context (Nusair and Kramer 
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Transbronchial lung biopsy (TBB) is a method to receive samples of lung parenchyma. In this 
technique, the bronchoscope is placed in a subsegmental bronchus and a biopsy forceps is passed 
forward into the periphery of the lung near the pleura in order to get a samle containing alveoli 
(Ioanas et al. 2001). Brushing, BAL, and TBBs are performed in the area with the greatest 
radiologic or visual abnormality. In addition to these techniques, endobronchial biopsies and 
bronchial washings from intrabronchial lesions are easily performed during the bronchoscopy. 
  
2.2. Microbes demonstrated in bronchoscopic specimens 
 
The clinical significance of various microbes detected in bronchoscopic specimens depends on the 
organ transplantated (LTx or other SOT), the microbiological methods used for demonstration of 
the pathogen, and other findings supporting the infection to be caused by the organism (e.g. 
radiographic appearance).  
 
Bacteria are the most commonly detected pathogens in BALF, but the bacterial findings have to be 
interpreted with caution. The mouth and upper airways are colonized with bacteria, and the 
differentiation between contamination and causative pathogens may be difficult. Quantitative 
bacterial cultures and the PSB technique have been developed to resolve this problem (Wimberley 
et al. 1979, Ioanas et al. 2001). Some bacteria, such as Legionella, Nocardia and M. tuberculosis, 
are always pathogens when found in respiratory specimens. 
 
The demonstration of Aspergillus in BALF (Fig. 4a) or PSB samples together with compatible 
clinical and radiographic features is suggestive of invasive aspergillosis, though histological 
confirmation of the diagnosis by biopsy or transthoracic needle aspiration is needed (Nicod et al. 
2001, Ascioglu et al. 2002, van der Bij and Speich 2003). Characteristic aspergillus 
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tracheobronchitis may also be detected during the bronchoscopy. Sole Aspergillus colonization in 
LTRs is associated with anastomotic complications and the development of invasive aspergillosis 
and, therefore, anti-fungal therapy is frequently initiated if Aspergillus is detected in bronchoscopic 
samples (Cahill et al. 1997, Nathan et al. 2000, Nunley et al. 2002, Dummer et al. 2004).  Candida 
sp. (mainly C. albicans) is frequently detected in BALF and PSB samples, but it usually represents 
a contamination from the upper airways without any major diagnostic significance (Rello et al. 
1998).  
 
P. carinii (Fig. 4b) is an intra-alveolar organism and is easily detected in BALF. Thus, BAL is the 
procedure of choice in establishing PCP with the diagnostic yield reaching up to 90 % (Schulmann 
et al. 1988, Baughman et al. 1994). TBBs taken together with BAL may further enhance the yield of 
bronchoscopy, but it is associated with an increased risk of complications (Baughman et al. 1994). 
 
BAL is generally found to be sensitive in detecting CMV in the lung, but methods for the 
demonstration of the virus as well as the definition of CMV pneumonia slightly differ between the 
studies (Schulman et al. 1991, Stenberg et al. 1993, Baz et al. 1996, Torres et al. 2000, Hopkins et 
al. 2002). Characteristic viral inclusions in BALF (Fig. 4 c) or demonstration of the virus in lung 
tissue (TBB) by immunohistochemistry, in situ hybridisation or viral inclusions are widely accepted 
as confirmation of CMV pneumonia (Ljungman et al. 2002a, Kotloff et al. 2004). The 
demonstration of CMV by viral culture, antigen detection or a DNA/RNA-based assay in BALF has 
been presented to allow presumptive diagnosis of CMV pneumonia when the clinical findings 
support the diagnosis (Trulock 1999, Preiksaitis et al. 2005). However, positive CMV cultures from 
BALF may reflect viral shedding into the respiratory tract without a major clinical significance 
(Ruutu et al. 1990, Mann et al. 1997). Similarly, detecting CMV DNA in BALF by the qualitative 
polymerase chain reaction (PCR) alone is considered insufficient in the diagnosis of CMV 
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pneumonia, but quantitative PCR has been found useful in recent studies (Ljungman et al. 2002a, 
Westall et al. 2004, Chemaly et al. 2004, Chemaly et al. 2005). The concomitant detection of CMV 
in BALF and blood is suggested to strengthen the evidence of CMV pneumonia (Preiksaitis et al. 
2005). 
 
Community-acquired respiratory viruses can be detected in BALF by antigen detection, PCR or 
culture (Weinberg et al. 2002). Although these viruses in BALF may reflect upper airway infection, 
they are able to cause pneumonia in SOT recipients and, therefore, should not be ignored (Palmer et 
al. 1998a, Speich and van der Bij 2001). Although there is no standard method to detect HHV-6 and 
HHV-7 in BALF, PCR-based methods have been used (Ross et al. 2001, Jacobs et al. 2003, 
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Figure 4. Characteristic findings in bronchoalveolar lavage fluid. A, Aspergillus hyphae; B, CMV 
viral inclusions in alveolar macrophages; C, pneumocysts in giemsa silver-methenamine stain. 
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2.3. Bronchoscopy in lung transplant recipients 
 
Bronchoscopy plays a central role in the management of LTRs. As in other SOT recipients, 
bronchoscopy is useful in the diagnosis of infection, but the procedure is also irreplaceable for the 
detection of acute rejection and airway complications in LTRs (Trulock 1997). The standard 
method for the diagnosis of acute rejection in the lung allograft is TBB with a sensitivity of 70 - 90 
% and specificity of 90 - 100 % (Scott et al. 1991, Trulock et al. 1992, Trulock 1997). At least five 
specimens containing lung parenchyma are needed to achieve an acceptable diagnostic yield. 
Although complications involving the bronchial anastomosis (e.g. dehiscence, stenosis, and 
bronchomalasia) have decreased since the early days of LTx, they still occur in some recipients 
(Ruttmann et al. 2005). Bronchoscopy is the key diagnostic procedure for these problems, and 
therapeutic interventions including balloon dilatation, laser recanalization or bronchial stent 
placement can also be performed through the bronchoscope (Higgins et al. 1994). 
 
The overall yield of bronchoscopy performed on LTRs in different studies is presented in Table 3. 
When performed on LTRs with clinical symptoms or findings referring to acute rejection or 
infection, bronchoscopy is a well-established diagnostic procedure with a considerably high yield 
(Chan et al. 1996, Hopkins et al. 2002). In addition, regularly scheduled bronchoscopies are 
performed on asymptomatic LTRs in order to detect clinically silent rejection or infection (Kukafka 
et al. 1997). Some authors have found a reasonably good diagnostic yield of about 50-60 % from 
these surveillance bronchoscopies (Table 3). In contrast, other studies have reported much lower 
yields, and routine bronchoscopies are not proven to decrease mortality or the development of BOS 
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Table 3. The diagnostic yield of bronchoscopy in lung transplant recipients. The criteria 

















FB, Flexible broncoscopy; TBB, Transbronchial biopsy; BAL, Bronchoalveolar lavage. 





2.4. Bronchoscopy in other solid organ transplant recipients 
 
The major indication for bronchoscopy in transplant recipients is suspected respiratory infection. 
The diagnostic yield of bronchoscopy in different SOT recipients is summarized in Table 4. The 
differences in the organ transplantated, antimicrobial and immunosuppressive medication given to 
the recipient, the bronchoscopic samples achieved, and the criteria for the microbiological diagnosis 
of pneumonia explain the variation between the studies. Nevertheless, the diagnoses established by 
bronchoscopy have been of considerable clinical significance in terms of leading to a change in the 
medical therapy in about 30 - 40 % of recipients (Torres et al. 2000, Sternberg et al. 1993). The 
most common causative microbes in SOT recipients have included bacteria, CMV, and P. carinii 





Study    Clinically indicated FBs          Surveillance FBs Specimens 
         N                  Yield (%)          N             Yield (%) studied 
    
   Trulock et al. 1992 88 69    90 57         TBB 
   Sibley et al. 1993 128 66    133 43         TBB 
   Guilinger et al. 1995 - -    355 25     TBB+BAL 
   Chan et al. 1996 282 67     39 58     TBB+BAL 
   Baz et al. 1996 69 48     157 26     TBB+BAL 
   Kesten et al. 1996a - -    102 10         TBB 
   Hopkins et al. 2002 344 86     836 19         TBB 
   Chakinala et al. 2004 - -    629 34         TBB 
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 FB, Flexible broncoscopy; BAL, bronchoalveolar lavage; PSB, protected specimen brush; TBB, transbronchial biopsy 
 NA, the proportion of bronchoscopies with each technique is not reported; 
 a Bronchial brushings were performed, but the technique was not specified.  
 
 
2.5. Complications of the bronchoscopy 
 
Bronchoscopy is considered a safe procedure in transplant recipients. However, major adverse 
events such as bleeding, pneumothorax, respiratory insufficiency, and extremely uncommon cases 
of fatality have been reported (Hopkins et al. 2002, Chhajed et al. 2003, Dransfield et al. 2004). The 
overall complication rate for bronchoscopy after LTx is reported to be approximately 2 - 9 % 
(Trulock et al. 1992, Hopkins et al. 2002, Dransfield et al. 2004). Although the complications 
related to bronchoscopy are not widely reported in SOT recipients other than LTRs, some major 
adverse events (cardiac arrhythmia, hypotension, and pneumothorax) were detected in HTRs by 
Schulman and co-workers (Schulman et al. 1988). The frequency of complications in mixed 
populations of immunocompromised patients has ranged from 2 to 21 % (Cazzadori et al. 1995, 
Rano et al. 2001, Jain et al. 2004).  This relatively large variation in the reported complication rates 
of bronchoscopy is mainly due to different definitions for complications (e.g. the amount of 




transplanted FBs (n) Yield of FB (%) 
Specimens 
    BAL(n)      PSB(n)     TBB(n) 
 
        Reference 
   
  
      Heart 39 62       + (35)       -      + (37)     Schulman et al. 1988 a 
      Kidney 58 55       + (58)       -       -     Sternberg et al. 1993 
      Kidney 33 61       + (33)       -      + (33)     Cazzadori et al. 1995 
      Kidney 91 69       + (91)       -       -     Reichenberger et al. 2001
      Kidney 64 59       + (NA)      + (NA)      + (NA)     Chang et al. 2004 
      Liver 60 48       + (58)      + (60)       -     Torres et al. 2000 
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Until today, eight herpes viruses have been isolated in man: HSV-1, HSV-2, CMV, varicella zoster 
virus (VZV), EBV, HHV-6, HHV-7, and HHV-8. CMV is a ubiquitous member of the herpes virus 
family with a world-wide seroprevalence of 50-100 % depending on the population studied (Sissons 
et al. 2002a, Alanen et al. 2005). In immunocompetent individuals, CMV infection usually 
manifests as a mild or asymptomatic infection during the first two decades of life. After primary 
infection, CMV is maintained in the host as latent infection controlled by the normally functioning 
immune system. Cytotoxic T lymphocytes and natural killer cells are probably the most important 
part of the defense mechanism against CMV, while humoral immunity may be of less importance 
(Harari et al. 2004). The main reservoir of latent CMV is thought to be blood mononuclear 
leukocytes and haematopoietic progenitor cells, though CMV latency is suggested also in other cell 
types (e.g. endothelial cells) (Taylor-Wiedeman et al. 1991, Kondo et al. 1994, Sissons et al. 
2002b). The immunosuppressive therapy, alloimmune responses, and release of proinflammatory 
cytokines place transplant recipients at risk of CMV reactivation from latency, amplification of the 
viral replication during active CMV infection, and development of tissue invasive CMV disease 
(Rubin 2001, Rowshani et al. 2005). Therefore, CMV remains as the most important single 








3.2. Definition and diagnosis of CMV infection 
 
In SOT recipients, CMV infection is defined as isolation of the virus or detection of viral proteins or 
nucleic acids in any body fluid (usually blood) or tissue specimen (Ljungman et al. 2002a). The 
CMV disease is confirmed by histological evidence of tissue invasion by the virus in the organ 
involved (Ljungman et al. 2002a, Zamora 2002). In addition, a characteristic syndrome after 
exclusion of other causes in the presence of CMV infection is considered to allow the presumptive 
diagnosis of the CMV disease (Zamora 2005, Preiksaitis et al. 2005). Several methods are currently 
available for the demonstration of CMV infection in transplant recipients. 
 
Culture. The recovery of CMV by culture has been a traditional method for the diagnosis of CMV 
infection. About 20 years ago the rapid shell vial assay using antibodies directed to CMV early 
antigens was developed to decrease the time needed for CMV culture (Gleaves et al. 1984, Gleaves 
et al. 1985). However, CMV cultures from blood are time-consuming and insensitive compared to 
CMV assays detecting pp65antigen or viral nucleic acids (Weinberg et al. 2000, van der Bij and 
Speich 2001). 
 
Antigenemia assay. The antigenemia assay is based on the detection of CMV antigen in peripheral 
blood leukocytes (antigenemia) by direct immunostaining using monoclonal antibodies against the 
CMV lower matrix phosphoprotein pp65 (van der Bij et al. 1988, The et. al. 1995). Quantitative 
results are expressed as the pp65-positive polymorphonuclear leukocytes (PMNL) per number of 
cells evaluated. Although some conflicting data exist, the antigenemia test is reliable in detecting 
CMV infection and predicting CMV disease (Egan et al. 1995, Kelly et. al. 2000, Weinberg et al. 
2000, Gerna et al. 2003). The need for immediate processing of samples, the variety of in-house 
modifications of the method, and the subjective nature of quantification are the main limitations of 
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the antigenemia test in clinical practice (Razonable et al. 2002). To resolve these difficulties, 
molecular assays to detect CMV DNA or RNA have been developed. 
 
DNAemia assays. The assays using PCR-based methods to detect CMV DNA in blood (DNAemia) 
are increasingly recognized as rapid and useful in demonstrating CMV infection.  Standardized and 
quantitative PCR assays using serum, plasma or peripheral blood leukocytes are commercially 
available. The hybrid capture assay is a non-PCR-based method to detect CMV DNAemia, but it 
has not been studied as widely as the PCR-based assays (Mazulli et al. 1999, Bhorade et al. 2001). 
A good correlation between the DNAemia and antigenemia levels has been detected in SOT 
recipients (Pang et al. 2003, Piiparinen et al. 2004). High CMV DNAemia has also been shown to 
predict and correlate to the CMV disease in most reports, though it was questioned in two recent 
studies (Rollag et al. 2002, Caliendo et al. 2002, Humar et al. 2004, Chemaly et al. 2004).  
 
RNAemia assays. The most commonly used method to detect CMV RNA in blood (RNAemia) is to 
demonstrate CMV late pp67 message RNA (mRNA) by nucleic acid sequence-based amplification 
(NASBA) (Blok et al. 1998). The presence of pp67-mRNAemia indicates active viral replication 
(Razonable 2002). Nevertheless, the assay is qualitative and has been found to be less sensitive than 
the DNAemia and antigenemia tests in most, but not all, previous studies (Gerna et al. 1999, 
Oldenburg et al. 2000, Blok et al. 2000, Gerna et al. 2003).  
 
Demonstration of CMV in  tissue specimens. Although the criteria differ from organ to organ, the 
diagnosis of the CMV disease should be confirmed in tissue specimens by virus isolation, 





3.3. Risk factors and impact of CMV infection 
 
 The CMV serostatus of the recipient (R) and donor (D) is the most important risk factor for the 
development and severity of CMV infection. Recipients with no previous history of CMV infection 
receiving a graft from a seropositive donor (R-/D+) are at high risk of primary infection which 
commonly manifests as severe disease, since no previous host defences against the virus are present 
(Wreghitt et al. 1989, Duncan et al. 1991). Without effective chemoprophylaxis a symptomatic 
CMV disease has been reported to occur in up to 91 % of the thoracic organ recipients with a D+/R- 
match, while the incidence in seropositive (R+) LTRs and HTRs ranges from 30 to 68 % and from 
17 to 46 %, respectively (Duncan et al. 1991, Merigan et al. 1992, Ettinger et al. 1993, Koskinen et 
al. 1993, Grossi et al. 1995, Camargo et al. 2001). When asymptomatic activation of the virus is 
included and no antiviral prophylaxis is used, CMV infection has been reported in up to 81 - 100 % 
and 51 - 93 % of the LTRs and HTRs at risk (D+ or R+), respectively (Duncan et al. 1991, Ettinger 
et al. 1993, Grossi et al. 1995, Soghikian et al. 1996, Camargo et al. 2001). In contrast, CMV 
infections in adult recipients with a D-/R- match are rare. It is difficult, however, to determine the 
exact incidences, since the risk factors and the definition for CMV infection differ between the 
studies. The risk of CMV infection is also dependent on the intensity of immunosuppression, 
especially the use of anti-lymphocyte antibodies, as well as on the organ transplanted (Jamil et al. 
2000, Zamora 2004a). The frequency and severity of CMV infections are higher in LTRs than in 
any other SOT recipients, probably due to the relatively intensive immunosuppressive therapy and 
the lung allograft carrying large amounts of the virus (Balthesen et al. 1993). Thus, some authors 





The harmful consequences of CMV infection in transplant recipients can be divided into direct 
mortality and morbidity of the clinical disease and indirect effects of the virus leading to acute and 
chronic allograft injury (Zamora 2004a). Clinical manifestations of the CMV disease include fever, 
leukopenia, trombocytopenia, pneumonia, hepatitis, encephalitis, myocarditis, retinitis, and 
gastrointestinal disease (Rubin and Fishman 1998, Ljungman et al. 2002a). In addition, 
asymptomatic CMV infection (e.g. antigenemia or DNAemia) is frequently detected in LTRs and 
HTRs (Gerna et al. 2003). An association between CMV infection and the development of chronic 
allograft injury (BOS and CAV) has been increasingly found, though this relationship is debated in 
some of the studies (Valantine et al. 1999, Westall et al. 2003, Potena et al. 2003, Tamm et al. 2004, 
Ruttmann et al. 2006). CMV infection is also suggested to increase the frequency and severity of 
the acute rejection episodes which, in turn, are risk factors for BOS and CAV (Sharples et al. 2002, 
Zamora 2004a, Taylor et al. 2006, Potena et al. 2006). The bidirectional relationship between CMV 
and allograft injury emerges from the perception that active CMV infection promotes acute 
rejection by inducing the production of inflammatory mediators, and the acute alloimmune 
response, in turn, activates latent CMV infection. Furthermore, the CMV infection-enhanced 
immune activation and smooth muscle cell (SMC) proliferation may lead to the occlusion of blood 
vessels and bronchioles and thereby to BOS and CAV (Lemström et al. 1993, Lemström et al. 1994, 
Tikkanen et al. 2001, Zamora 2004a, Lemström et al. 2005). Through its suppressive effects on host 
defences CMV has been shown to increase susceptibility to opportunistic infectious agents, such as 
fungi (Yeldandi et al. 1995). CMV may also work synergistically with other pathogens to cause the 














Figure 5. The effects of cytomegalovirus (CMV) infection in lung and heart transplant recipients. 
ATG, antithymocyte globulin; TNF-α, Tumour necrosis factor α; NF-κB, nuclear factor-κB; IFN-γ, interferon-γ; 
SMC, smooth muscle cell; BOS, bronchiolitis obliterans syndrome; CAV, cardiac allograft vasculopathy; 
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3.4. Prevention and treatment of CMV infection 
 
To prevent and treat CMV infections, antiviral agents may be administered to all recipients 
considered to be at risk of CMV infection (prophylaxis), when a positive laboratory test or a certain 
cut-off value of a quantitative assay is detected (pre-emptive therapy) or when a symptomatic CMV 
infection occurs (rescue therapy) (van der Bij and Speich 2001). The drug of choice for the therapy 
and prophylaxis against CMV infection is ganciclovir. Its prodrug valganciclovir has recently been 
shown effective in the pre-emptive therapy against CMV infection after SOT (Devyatko et al. 2004, 
Diaz-Pedroche et al. 2006). The advantage of valganciclovir is its high bioavailability in oral 
administration (Wiltshire et al. 2005). 
 
Prophylaxis with intravenous ganciclovir or oral valganciclovir is effective in preventing CMV 
infection and disease in LTRs and HTRs (Merigan et al. 1992, Duncan et al. 1992, Soghikian et al. 
1996, Humar et al. 2005). Chemoprophylaxis against CMV may also reduce the risk of BOS and 
CAV (Potena et al. 2006, Ruttmann et al. 2006). Furthermore, CMV prophylaxis decreased the all-
cause mortality during the first postoperative year after SOT in two recent meta-analyses, but 
studies on LTRs were not included (Hodson et al. 2005, Kalil et al. 2005). Universal 
chemoprophylaxis against CMV is recommended to all LTRs at risk (D+ or R+) and to HTRs with 
a D+/R- match, but the optimal regimen and duration of prophylaxis are unclear (Rubin 2000, 
Zamora et al. 2005). Nevertheless, CMV infections occur after cessation of the prophylaxis 
necessitating the surveillance and treatment of CMV infection also when anti-CMV prophylaxis is 
initially used (Duncan et al. 1994, Soghikian et al. 1996, Humar et al. 2005, Potena et al. 2006, 




The strategy of the pre-emptive therapy is based on the detection of CMV infection (e.g. 
antigenemia, DNAemia or RNAemia) and the institution of an antiviral therapy before a full-blown 
CMV disease develops. The pre-emptive therapy needs to be guided by a convenient, reliable, and 
timely diagnostic surveillance test which will identify CMV infection quickly enough to prevent the 
CMV disease to develop. Traditionally, the CMV pp65 antigenemia test has been used for 
surveillance of CMV infection and has proved reliable in guiding the pre-emptive therapy (Egan et 
al. 1998, Kelly et al. 2000). Assays detecting CMV DNAemia by PCR are recommended as good 
alternatives to the antigenemia test in guiding the pre-emptive therapy (Rubin 2000, Zamora 2005, 
Preiksaitis et al. 2005). However, their overall usefulness is not widely studied in HTRs and LTRs. 
Although in some studies the pp67 mRNAemia test has been relatively insensitive, Gerna and 
coworkers regarded this assay as an efficient method in the guidance of the pre-emptive therapy 
(Blok et al. 2000, Gerna et al. 2000, Gerna et al. 2003).  
 
While modern treatment and prophylaxis strategies have undoubtedly declined the mortality and 
morbidity associated with CMV infections, the optimal tests and relevant thresholds for guidance of 












4. Human herpesvirus(HHV)-6 and HHV-7 in transplant recipients 
 
4.1. HHV-6 and HHV-7 
 
HHV-6 and HHV-7, together with their close relative CMV, form the beta-herpesvirus family 
(Black 1999, Dockrell 2003). HHV-6 is a lymphotropic virus which uses a CD46 molecule as 
receptor and may also infect other cell types, such as monocytes or even epithelial and endothelial 
cells (Dockrell and Paya 2001, De Bolle et al. 2005). HHV-7 uses a CD4 molecule as receptor and 
is more selectively lymphotropic (Black 1999). The primary HHV-6 and -7 infection manifests as 
exanthema subitum and roseola during early childhood (Yamanishi et al. 1988, Black 1999). As the 
seroprevalence of HHV-6 and -7 in the adult population is over 90 %, primary infections in adult 
individuals are rare (Levy et al. 1990, Clark et al. 1993, Humar 2006).  
 
4.2. Impact of HHV-6 and HHV-7 
 
After primary infection, HHV-6 and HHV-7 can establish a latent infection for lifetime and be 
reactivated during immunosuppression. Reactivation of HHV-6 and, to a lesser extent, of HHV-7 
has been reported to be relatively common after solid-organ and stem cell Tx (Griffiths et al. 1999, 
Lautenschlager et al. 2000, Mendez et al. 2001, Emery 2001, Yoshikawa 2004, Volin et al. 2004). 
However, most of the studies after SOT have evaluated liver transplant recipients, and only three 
studies have included LTRs. Jacobs and coworkers detected HHV-6 in blood by PCR or culture in 
66 % of the LTRs, and Neurohr et al. found HHV-6 DNA from the BALF in 31 % of the patients 
(Jacobs et al. 2003, Neurohr et al. 2005). In contrast, Michaelides et al. did not detect HHV-6-
DNAemia in any of the 26 LTRs studied (Michaelides et al. 2002). Until today, no prospective 
studies on HHV-7 after LTx are available. 
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There is no standard assay for the detection of HHV-6 and -7. Most of the studies have employed 
PCR-based methods, but the detection of viral DNA in peripheral blood or in leukocytes is also 
possible in the case of latent infection (Ljungman 2002b, Razonable et al. 2005). Quantitative PCR 
methods have been developed to resolve this problem, but clinically relevant threshold levels for 
HHV-6 or -7 DNAemia are not known (Yoshikawa 2004). The demonstration of HHV-6- and 
HHV-7-specific antigens in peripheral blood mononuclear cells (PBMCs) provides an alternative 
method to detect active viral replication (Lautenschlager et al. 2000). 
 
In transplant recipients most of the HHV-6 and HHV-7 activations are asymptomatic (Jacobs et al. 
2003, Razonable et al. 2005, Humar 2006). Nevertheless, HHV-6 has been associated with multiple 
clinical manifestations (skin rashes, hepatitis, bone marrow suppression, interstitial pneumonitis, 
and encephalitis), and even life-threatening infections have been reported (Singh et al. 1997, Zerr et 
al. 2002, Volin et al. 2004, De Bolle et al. 2005). The causal relationship between the symptoms 
and HHV-6 is, however, often uncertain, and other infections occurring concomitantly with HHV-6 
may be responsible for the clinical manifestations. Although an increasing number of studies 
evaluating also HHV-7 in SOT recipients exists, the clinical significance of this virus is still poorly 
understood (Griffiths et al. 1999, Razonable et al. 2003, Razonable et al. 2005). 
 
HHV-6 activation has been associated with allograft rejection and dysfunction in liver transplant 
recipients (Griffiths et al. 1999, Lautenschlager et al. 2000, Humar et al. 2002). In a recent study on 
LTRs, the demonstration of HHV-6 in BALF also increased the risk of BOS (Neurohr et al. 2005). 
Furthermore, the concomitant appearance of HHV-6 or HHV-7 together with CMV is frequently 
detected and may lead to a more severe viral infection suggesting interactions between the three 
beta-herpesviruses (DesJardin 2001, Humar et al. 2002, Lautenschlager et al. 2002, Humar 2006). 
These findings raise the possibility that all three beta-herpesviruses may be involved in the indirect 
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effects originally suggested only to be due to CMV and the manifestations of the CMV disease may 
be partly related to HHV-6 or -7.   
 
4.3. Prevention and treatment of HHV-6 and HHV-7 
 
 Ganciclovir, foscarnet, and cidofovir have in vitro activity against HHV-6 and HHV-7 (Ljungman 
2002b, De Clercq et al. 2001). Although there are several case reports suggesting clinical response 
on HHV-6-related disease by ganciclovir or foscarnet therapy, no controlled studies assessing the 
efficacy of antiviral agents in the treatment of HHV-6 or -7 have been performed (Mookerjee and 
Vogelsang 1997, Zerr et al. 2002, Ljungman 2002b). Antiviral prophylaxis with ganciclovir may 
decrease or delay the appearance of HHV-6, but compelling data on the usefulness of antiviral 
prophylaxis against HHV-6 and -7 is lacking (Razonable et al. 2005, Galarraga et al. 2005). No 















AIMS OF THE STUDY 
 
 The overall purpose of this study was to expand the knowledge in the infectious complications after 
lung and heart transplantation with a special emphasis on the diagnostic usefulness of bronchoscopy 
and the detection of CMV, HHV-6, and HHV-7 infections. 
 
The specific aims of the study were the following: 
 
1)   to evaluate the diagnostic yield, clinical impact, and safety of the bronchoscopy in HTRs with 
      a suspected respiratory infection; 
 
2)   to evaluate the diagnostic yield, clinical impact, and safety of bronchoscopy in the diagnosis 
      and surveillance of respiratory infections and other postoperative complications in LTRs; 
 
3)   to compare the CMV antigenemia, DNAemia, and mRNAemia tests in detecting CMV infection 
      in thoracic organ transplant recipients with a special emphasis on the feasibility of the 
      DNAemia and mRNAemia assays in guiding the pre-emptive therapy; 
 
4)   to determine the incidence of HHV-6 and HHV-7 antigenemia, evaluate their association with 
      clinical symptoms, and describe the effect of the antiviral prophylaxis against CMV, HHV-6, 











 A total of 105 thoracic organ transplant recipients operated at Helsinki University Central Hospital 
were included in the studies (Table 5). Heart-lung transplant recipients (HLTRs) are included in the 
group of LTRs in the text, if not mentioned separately. 
 
Antithymocyte globulin (ATG) (1.25 – 2.5 mg/kg/day) was given to all HTRs/HLTRs and 21 LTRs 
for 1-5 postoperative days (POD). The maintenance immunosuppressive regimen consisted of CyA 
(target trough level of 200-400 ng/ml), AZA 1-2 mg/kg/day or MMF 2-3 g/day, and 
methylprednisolone starting with 1 g perioperatively and tapered down to 0.1 mg/kg/day. One HTR 
received tacrolimus instead of CyA (Table 5). Acute rejection was treated with methylprednisolone 
0,5-1 g daily for three days and with murine monoclonal antibody (OKT-3)  or ATG if needed. 
 
Antibiotic prophylaxis (usually third generation cephalosporins and/or vancomysin) was given for 
the immediate perioperative period to prevent bacterial infections. Pneumocystis carinii prophylaxis 
was initiated in 1992 and consisted of 1-2 tablets (160 mg of thrimethoprime and 800 mg of 
sulfamethoxazole) of Co-trimoxazole once daily three days a week or inhaled pentamidine every 
four weeks if the patient did not tolerate Co-trimoxazole. The prophylaxis was continued for six 
months in the 35 HTRs operated after 1992 and lifelong in all LTRs if tolerated. The antiviral 
prophylaxis is presented in the Section 3.3. 
  

































                 
 
                      a Bronchiectasis, Sdr. Kartagener, Cardiomyopathy, Bronchiolitis obliterans, 
                    Coronary artery disease, re-transplatation.             
                    COPD, chronic obstructive pulmonary disease; CyA, Cyclosporine; AZA,  
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Figure 6. Timing of the transplantation and number of the patients in the Studies I – IV. 
  
     Total number of patients 105 
  
     Male/female 69/36 
  
     Age, mean (range) 46 (14 – 68) 
  
     Type of transplantation  
            Lung 36 (34 %) 
            Heart-lung 20 (19 %) 
            Heart 49 (47 %) 
  
  
     Indication for lung or heart-lung 
     transplantation  
             α1-antitrypsin deficiency   11 
            Idiopathic pulmonary fibrosis 10 
            Congenital heart disease 10 
            COPD / Emphysema 8 
            Pulmonary hypertension 6 
            Lymphangioleiomyomatosis 3 
            Cystic fibrosis 2 
            Othera 6 
  
  
     Indication for heart transplantation  
            Cardiomyopathy 27 
            Coronary artery disease 17 
            Myocarditis 3 
            Congenital heart disease 2 
  
  
      Maintenance immunosuppression  
            CyA + AZA + Cs 76 (72 %) 
            CyA + MMF + Cs 28 (27 %) 




1.1. Bronchoscopies performed on heart and lung transplant recipients (I, II) 
 
All the consecutive bronchoscopies performed at Helsinki University Central hospital on HTRs 
between May 1988 and December 2001 (Study I) and on LTRs between February 1994 and 
November 2002 (Study II) were analysed. Bronchoscopies with BAL were performed when a 
respiratory infection or rejection (LTRs) was suspected (clinically indicated bronchoscopies). In 
addition, LTRs were followed up by bronchoscopies performed weekly during the first 
postoperative month, then every 1-3 months during the first year posttransplant, and once a year 
thereafter (surveillance bronchoscopies). Transbronchial lung biopsy was performed on the LTRs 
one, three, six, nine, and 12 months after Tx and when acute rejection was suspected. 
 
Thirty-five HTRs with a suspected lower respiratory tract infection underwent 47 bronchoscopies, 
while a total of 609 procedures were performed on 40 LTRs during the time periods studied. The 
number of bronchoscopies analysed in the diagnostic setting were 44 in HTRs and 472 in LTRs 
(190 clinically indicated and 282 surveillance bronchoscopies). The remaining  bronchoscopies 
were follow-up procedures performed during the same episode of infection or rejection and did not 
yield any additional diagnostic information. However, all bronchoscopies were reviewed to detect 
potential complications of the procedure. 
 
1.2. Lung and heart transplant recipients monitored by CMV antigenemia, DNAemia, and 
mRNAemia tests (III) 
 
A total of 21 thoracic organ transplant recipients (seven LTRs and 14 HTRs) operated between 
December 2000 and April 2003 at Helsinki University Central Hospital were prospectively 
monitored with CMV antigenemia, DNAemia (PCR), and mRNAemia (NASBA) blood tests for a 
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12-month period. Blood samples were collected weekly during the hospital stay, once every two 
weeks until six months, and monthly during 6-12 months postoperatively. Additional blood samples 
were drawn if CMV infection was suspected or detected. Altogether 448 blood samples were 
received for CMV assays. Two (0.4 %), eight (1.8 %), and 25 (5.6 %) of the samples were not 
applicable or valid for the antigenemia test, PCR, and NASBA, respectively, and,  due to long 
geographic distances, 28 blood samples could not be collected as required in the follow-up protocol. 
 
1.3. Lung transplant recipients monitored for CMV, HHV-6, and HHV-7 (IV) 
 
Twenty-two LTRs operated on at Helsinki University Central Hospital between December 2000 and 
October 2004 were prospectively monitored for the three β-herpesviruses (HHV-6, HHV-7, and 
CMV). Blood samples for detection of HHV-6, HHV-7, and CMV antigens were collected weekly 
during the hospital stay and at each outpatient visit thereafter. Additional blood samples were 
obtained if a viral infection was suspected or a CMV infection was detected. The three β-
herpesviruses were also analysed from BALF. Altogether, 324 blood specimens (a median of 14 per 














2.1. The bronchoscopic procedures 
 
The fiberoptic or videobronchoscope was used for the bronchoscopies. Before BAL bronchial 
brushing with PSB was performed. BAL was performed by wedging the tip of the bronchoscope 
into the segmental bronchus of the area with the greatest radiologic or visual abnormality. A total of 
160-200 ml of sterile physiologic saline was instilled in 20 ml aliquots. Gentle manual suction was 
applied to retrieve the saline. Transbronchial biopsies were performed only on the LTRs. TBBs 
were taken under fluoroscopic guidance from the areas of maximal radiologic infiltrate using 
alligator forceps. In case of no parenchymal infiltration the samples were taken from every lobe. 
Five to six TBB samples were collected per procedure. 
 
2.2. Specimens received by the bronchoscopy 
 
The BALF and PSB samples were cultured for bacteria and fungi. Cultures for mycobacteria, 
legionellae, and viruses as well as staining for fungi were made from BALF. Varicella zoster, 
Herpes simplex, Legionella pneumophilia, and common respiratory viruses were identified by 
antigen detection in BALF. Giemsa silver-methenamine stain from BALF and, since 1992, also 
antigen detection was used to detect Pneumocystis carinii. The demonstration of CMV is described 
in the Section 3.1. All BALF left from the microbiological studies was used for cytological 
investigations to determine the total and differential cell count, viral inclusion bodies, microbes, and 
atypical cells. The TBB specimens were examined histologically and for CMV-pp65 and P. carinii 
antigen expressions. In addition to these routine tests, HHV-6 and -7 were demonstrated from 
BALF in the Study IV, as described in the Section 4. 
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2.3. Significance of the findings received by the bronchoscopy  
 
The bacteria in the BALF or PSB samples were considered significant if they were known 
respiratory pathogens and the patient suffered from a lower respiratory tract infection. The bacteria 
cultured from the surveillance bronchoscopic samples were considered significant if the same 
organism was later detected in BALF or PSB samples during symptomatic respiratory infection. In 
the LTRs colonizations with Pseudomonas aeruginosa or Stenotrophomonas maltophilia were 
considered clinically significant if an antibiotic therapy was initiated by the clinician.  
 
In the LTRs the detection of Aspergillus species in the bronchoscopic samples was always regarded 
as significant. If characteristic membranes and ulcerations were detected together with Aspergillus 
airway colonization, the diagnosis was Aspergillus tracheobronchitis. Invasive Aspergillosis was 
defined as a histopathologic or cytopathologic finding showing hyphae associated with tissue 
damage (Ascioglu et al. 2002). The Candida species cultured from the bronchoscopic samples were 
not considered significant unless histopathologic evidence of invasive fungal pneumonia or positive 
blood culture was present. 
 
Pneumocystis carinii and non-CMV viruses were always regarded as clinically significant 
pathogens when detected in the BALF or TBB specimens. The CMV pneumonia (disease) was 
defined as described in the Section 4.2.  
 
The diagnosis and severity of acute rejection in the TBB specimens were defined according to the 
ISHLT criteria (Yousem et al. 1996). The anastomotic complication was defined as endobronchial 
stricture or granulation tissue resulting in symptoms or functional impairment of the recipient and 
necessitating an intervention. 
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3.  CMV infection 
 
3.1. Demonstration of CMV  
 
CMV antigenemia test (I – IV) 
The detection of CMV antigens in peripheral blood, BALF, and tissue specimens was based on the 
standard CMV pp65 antigen test (The et al. 1995). For detection of CMV antigenemia 
cytocentrifuge preparations were prepared onto microscope slides, after which a three-layer indirect 
immunoperoxidase technique and a monoclonal antibody against CMV pp65 antigen (Biotest, 
Frankfurt, Germany) were used (Fig. 7). CMV antigenemia in peripheral blood was measured by 
calculating CMV pp65 positive leukocytes per 50 000 PMNL on the slide. 
 
CMV DNAemia (PCR) test (III)  
The Cobas Amplicor CMV Monitor Test (Roche, Indianapolis, USA) was used for quantification of 
CMV DNA in the EDTA blood samples. The test was done according to the manufacturer’s 
instructions and as described (Piiparinen et al. 2002 and 2004). The lower detection limit of the 
assay was 400 copies/ml and the linear range 400 - 100,000 copies/ml of plasma. 
 
CMV mRNAemia (NASBA) test (III) 
CMV mRNAemia was demonstrated by the NucliSens assay (bioMérieux, Boxtel, Netherlands) 
according to the manufacturer’s instructions. The assay uses a qualitative nucleic acid sequence-






Demonstration of CMV in BALF and tissue specimens 
CMV was demonstrated in the BALF and tissue specimens (e.g. TBB) by immunohistochemistry 
using the detection of CMV pp65antigen-positive cells or by detecting characteristic intracellular 
inclusion bodies (Ljungman et al. 2002a). In addition, rapid shell vial cultures were performed from 
the BALF samples to detect CMV. 
 
3.2. Diagnosis of CMV infection 
 
CMV infection was defined as a positive CMV antigen test in blood or BALF. In the Study III CMV 
infection was also demonstrated by the CMV DNAemia and mRNAemia tests. However, only the 
CMV antigenemia test was used to guide the antiviral therapy.  
 
The diagnosis of the CMV disease (e.g. pneumonia) was confirmed when symptoms and/or findings 
referring to a viral infection were present in combination with the detection of characteristic 
intracellular inclusion bodies or CMV pp65-antigen in tissue specimens or BALF. However, sole 
CMV pp65-antigen positive cells in BALF were not accepted for the diagnosis of the CMV disease 
in the Study II, though this finding was considered significant in terms of demonstrating CMV 
infection. In that study, one of the aims was to test the usefulness of the CMV antigen test and 
culture to detect otherwise confirmed CMV pneumonia.  
 
3.3. Prevention and treatment of CMV infection 
 
Antiviral prophylaxis against CMV for a minimum of three postoperative months was given to the 
LTRs since January 1995 if the recipient or donor was seropositive (R+ or D+). Valganciclovir was 
used as CMV prophylaxis to one HTR (R-/D+) in the Study III, while all the other HTRs and LTRs 
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at low risk of CMV infection (R-/D-) received oral acyclovir (600 mg/day) for three postoperative 
months. The routine prophylactic strategy changed over the study years, as orally administered 
ganciclovir and valganciclovir became available. The length and dosing of the prophylaxis also 
varied due to the side-effects of the drugs, the renal function of the recipient, and the antirejection 
therapies needed. Details of the pretransplant CMV-serostatus and prophylaxis against CMV in the 
prospective studies (III and IV) are presented in Table 6. 
 




Factor             III                        IV 
   
     Pretransplant CMV-serostatus   
            R+/D+ 14 (67 %) 14 (63 %) 
            R+/D-   6 (28 %)   4 (18 %) 
            R-/D+ 1 (5 %) 1 (4 %) 
            R-/D- 0 (0 %)   3 (14 %) 
   
     CMV prophylaxis   
            iv.GAN/po.GANa (7-90 POD) 3 3 
            po.GANb (7-90 POD) 2 2 
            po. valGANc (7-90 POD) 2 2 
            po. valGANc (7-120 POD)  4 
            po. valGANc (7-180 POD) 1 5 
            po. valGANc (7-210 POD)  2 
            po. valGANc (7-270 POD)  1 
            No prophylaxisd 13
e 3f 
   
 
CMV, Cytomegalovirus; R, Recipient; D, Donor 
GAN, ganciclovir; POD, postoperative days; valGAN, valganciclovir 
a Iv. GAN 10 mg/kg/day 7-21 POD, 5 mg/kg/day 22-28 POD and po. GAN 3g/day 29-90 POD 
b 3g/day (The doses of GAN were adjusted for renal function) 
c 450-900 mg/day (The dose was adjusted for renal function and body weight) 
d Acyclovir (600 mg/day) until POD 90 was given to prevent other herpesvirus diseases 
 e Heart transplant recipients 
 f Lung transplant recipients at low risk of CMV infection (R-/D-) 
 
In addition to the universal prophylaxis, a pre-emptive antiviral therapy against CMV infection was 
increasingly used from the late 1990s based on the results of the CMV antigenemia test. Before the 
year 2001 the decision of initiating pre-emptive therapy was made by the attending physician. In the 
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prospective studies (III and IV) the pre-emptive treatment strategy was as follows: Antiviral therapy 
was initiated with pp65-positive leukocytes ≥2 and ≥10 per 50 000 PMNL in the LTRs and HTRs, 
respectively. HTRs with an antigenemia level from 5 to 9 pp65-positive leukocytes received 
antiviral therapy immediately or the assay was controlled in one week and the therapy was initiated 
if increasing antigenemia was detected. All patients with symptomatic CMV infection or CMV 
disease received antiviral therapy regardless of the antigenemia level (rescue therapy). Intravenous 
ganciclovir (5 mg/kg b.i.d.) or peroral valganciclovir (900 mg b.i.d.) was used as antiviral therapy 
for CMV infection. The treatment was continued for a minimum of 14 days and until the CMV 
antigenemia test was negative. 
 
4. Demonstration of HHV-6 and HHV-7 (IV) 
 
HHV-6 and HHV-7 were demonstrated by detecting the virus-specific antigens in the PBMCs and 
BALF cells (Fig. 7). The PBMCs were isolated by Ficoll-Isopaque density gradient centrifugation 
and cytocentrifuged onto microscope slides. The presence of HHV-6 antigens in the 
cytopreparations of the PBMCs and BALF cells was demonstrated by indirect immunoperoxidase 
staining and by monoclonal antibodies (MAB8533 and MAB8535; Chemicon Inc., Temecula, CA, 
USA) against an early HHV-6 specific antigen and an HHV-6 variant B virion protein, as described 
(Lautenschlager et al. 2000). Normal mouse-IgG was used as negative control for non-specific 
binding. A peroxidase-conjugated rabbit anti-mouse (Dako, Copenhagen, Denmark) antibody and a 
peroxidase-conjugated goat anti-rabbit antibody (Zymed, San Francisco, CA, USA) were used as 
second and third antibodies. The reaction was revealed by 3-amino-9-ethyl carbazole solution 
containing hydrogen peroxide, and Mayer’s haemalum was used for counterstaining. 
Concomitantly, HHV-7-specific antigens were demonstrated in the cytocentrifuge preparations by 
using immunoperoxidase staining with monoclonal antibodies (Biodesign International, Saco, ME, 
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USA), as described (Lautenschlager et al. 2002). No cross-reactivity between the antibodies or non-
specific staining was recorded. 
 
  





 A                                                B                                                 C 
Figure 7. CMV pp65-antigen-positive granulocyte (A). Human herpesvirus-6 (B) and human 
herpesvirus-7 (C) antigen-positive lymphocytes. Positive cells are pointed with arrows.  
Figures provided from the Transplant Unit Research Laboratory, University of Helsinki and Helsinki University Central 
Hospital. Reprinted from the orginal publication (IV) with the permission from the publisher (Elsevier and ISHLT).  
 
 
5. Statistical Analyses 
 
 The diagnostic yield of bronchoscopy in different time intervals and patient groups was compared 
using the chi-square test. The time-related appearance of each β-herpesvirus and the time to the first 
CMV infection in recipients with and without prophylaxis were compared using the Kaplan-Meier 
method. Differences between the groups were analysed by the log-rank test. The number of CMV 
pp65-antigen-positive leukocytes and the CMV DNAemia level were compared using Spearman´s 
rank correlation test. The CMV infections positive by different assays in the Study III and the 
patient groups with different CMV prophylaxis in the Study IV were compared by Fisher’s exact 
test. Receiver-operating characteristic (ROC) curves were performed to determine the optimal 
threshold CMV DNAemia levels for initiation of the pre-emptive antiviral therapy when different 
CMV antigenemia cut-off levels were used as a reference. A statistical significance was accepted 
for p < 0.05. 
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specific staining was recorded. 
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1. Utility of bronchoscopies (I, II) 
 
The overall diagnostic yield of the clinically indicated bronchoscopies was 18/44 (41 %) and 
115/190 (61 %) in the HTRs and LTRs, respectively. When only the microbiological diagnosis of 
infection was considered, the diagnostic yield for the HTRs remained 41 %, while it was 51 % in 
the LTRs. The procedure caused a change in the medical therapy in 105/190 (55 %) and 14/44 (32 
%) of the clinically indicated bronchoscopies performed on the LTRs and HTRs, respectively.  
Surveillance bronchoscopies performed on the LTRs established a diagnosis in 43/282 (15 %) of the 
procedures, and the findings led to a change in the previous treatment of the patient in 16/282 (6 %) 
of the cases. The diagnostic yield of bronchoscopy was highest from one to six months 
posttransplant when compared to all the other time intervals in both the HTRs and LTRs (p < 0.05). 
The overall diagnostic yield was 26/70 (37 %) and 8/92 (9 %) for TBBs performed on the LTRs in 
the clinically indicated and surveillance bronchoscopies, respectively (p < 0.001). None of the 
surveillance TBBs, but 19/70 (27 %) of the clinically indicated TBBs directly changed the drug 
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2. Diagnoses established by the bronchoscopy (I, II) 
 
The diagnoses established by the bronchoscopy and significant microbes detected in the 
bronchoscopic specimens are presented in Table 7.   
 
Table 7. Diagnoses established by the bronchoscopy in HTRs and LTRs. From two to four 
diagnoses were established by one bronchoscopy in 4/44 (9 %) and 40/190 (21 %) of the 





cFBs (n = 44) 
LTRs 
cFBs (n = 190) 
LTRs 
sFBs (n = 282) 
    
Infection 18 (40.9 %) 96 (50.5 %) 34 (12.1 %) 
    
  P. carinii 9 (20.5 %) 18 (9.5 %) 5 (1.8 %) 
    
  CMV 9 (20.5 %) 27 (14.2 %) 7 (2.5 %) 
    
  Bacteria 1 (2.3 %) 57 (30.0 %) 9 (3.2 %) 
    
       P aeruginosa  11 5 
       P aeruginosa + Str.pneumoniae  1  
       Stenotroph. maltophilia  7 3 
       Staph. aureus  10  
       Staph. aureus + Str. pneumoniae  1  
       Str. pneumoniae  6  
       H influenzae  3 1 
       M catarrhalis  4  
       H influenzae + M catarrhalis 1   
       Nocardia  3  
       Staph. epidermidis  3  
       Klebsiella oxytoca  2  
       L pneumophila  2  
       Other 
a  4  
    
  Aspergillus 2 (4.5 %) 7 (3.7 %) 10 (3.5 %) 
    
  Viruses other than CMV 1 (2.3 %) 11 (5.8 %) 6 (2.1 %) 
    
       HSV  1 2 
       VZV   1 
       RSV 1 4  
       RSV + VZV  1  
       Influenzavirus  2 2 
       Parainfluenzavirus  2  
       Parainfluenzavirus + HSV  1  
       Adenovirus   1 
    
  Mycobacteria  2 (1.1 %)  
    
Acute rejection  21 (11.1 %) 8 (2.8 %) 
  Grade 1  10 8 
  Grade ≥ 2  11  
    
Airway complication  12 (6.3 %) 1 (0.4 %) 
    
Other b 1 (2.3 %) 4 (2.1)  
    
No diagnosis 26 (59.1 %) 75 (39.5 %) 239 (84.8 %) 
    
                   HTR, heart transplant recipient; LTR, lung transplant recipient; cFB, clinically indicated flexible 
                   bronchoscopy; sFB, surveillance flexible bronchoscopy 
                   a E faecalis, E coli, S marcescens, Mycoplasma 
                   b Endobronchial adenocarcinoma (HTR), Eosinophilic pneumonia (2), COP, bronchiolits obliterans. 
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Pneumocystis carinii was detected in 9/44 (20 %) and 23/472 (5 %) of the bronchoscopic specimens 
from the HTRs and LTRs, respectively. In the LTRs 15/23 (65 %) of the P. carinii infections were 
breakthrough infections detected during adequate chemoprophylaxis (eight during co-trimoxazole 
and seven during inhaled pentamidine). The characteristics of the episodes with P. carinii detected 
in the bronchoscopic samples from the LTRs are presented in Table 8. In the 21 HTRs who had 
been given prophylaxis two episodes of P. carinii infections occurred two and four months after 
finishing the chemoprophylaxis. 
 
Table 8.  Pneumocystis carinii detected in bronchoscopic specimens in lung transplant recipients. 
 
 
          TMP-SMZ, Co-trimoxazole; IP, inhaled pentamidine, FB flexible bronchoscopy, HRCT, high-resolution  
          computed tomography, BALF, bronchoalveolar lavage fluid, TBB, transbronchial lung biopsy.  




   
 P. carinii prophylaxis  
 TMP-SMZ     IP   None 
Total  
(% of P.carinii infections) 
      
No. 11 8 4     23 (100 %)  
     
Type of FB     
        Clinically indicated FB 9 5 4 18 (78 %) 
        Surveillance FB 2 3 0   5 (22 %) 
     
Infiltrate on HRCT or chest radiograph     
        Infiltrate 7 4 2 13 (57 %) 
        No Infiltrate 4 4 2 10 (43 %) 
     
Time after transplantation     
        < 30 days 3 0 2   5 (22 %) 
        31-360 days 5 3 0   8 (35 %) 
        361-720 days 2 3 1   6 (26 %) 
        > 720 days 1 2 1   4 (17 %) 
     
P. carinii detected in     
        BALF + / TBB not done 7 4 3 14 (61 %) 
        BALF + / TBB + 1 1 1   3 (13 %) 
        BALF + / TBB - 1 3 0   4 (17 %) 
        BALF -  / TBB + 2 0 0 2 (9 %) 
     
54
 
Cytomegalovirus was detected by the pp65-antigen test or viral inclusions in the specimens from 
34/472 (7 %) of the bronchoscopies performed to LTRs. The positive predictive values for CMV 
pneumonia by the CMV antigen test and the CMV culture in the BALF from the symptomatic 
recipients (clinically indicated bronchoscopy) were 24.0 % and 9.7 %, respectively. In addition, 
CMV was detected in the BALF from the surveillance bronchoscopies by the antigen test in 7/282 
(3 %) and by the culture in 63/282 (22 %) of the cases. Nine cases of CMV pneumonia were 
detected in the HTRs carrying a mortality rate of 44 % (4/9). Bacteria were the most frequently 
detected significant microbes in the LTRs, while the microbiological diagnosis of bacterial 
pneumonia was received in only one HTR. However, 73 % of the HTRs were treated with empiric 
antibiotics before the bronchoscopy. Aspergillus species detected in the bronchoscopic samples 
were related to histologically proven invasive Aspergillus infection in four recipients (two LTRs 
and two HTRs). All the other cases revealed Aspergillus airway colonization in the LTRs. None of 
the Candida species cultured from the bronchoscopic samples were related to invasive Candida 
infection. All grade 2-3 and 6/10 of the grade 1 symptomatic rejections detected in the clinically 
indicated TBBs were treated with antirejection therapy, while no therapy was initiated for the eight 
asymptomatic rejections (grade 1) diagnosed by surveillance TBBs. 
 
3. Safety of the bronchoscopies (I, II) 
 
There were no fatalities associated with the bronchoscopies. The procedure provoked respiratory 
insufficiency in three and myocardial ischaemia in one of the HTRs. Five LTRs suffered from 
respiratory insufficiency demanding ventilatory assistance, and one LTR developed severe 
hypoxemia disturbing the procedure. Four bronchoscopies were prematurely interrupted due to 
bleeding in the LTRs. Two spontaneously resolving pneumothoraces and one local pulmonary 
haemorrhage were detected after TBB. Thus, 17 clinically significant complications were detected 
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giving a complication rate of 2.1 % and 9.1 % for the bronchoscopies performed on the LTRs and 
HTRs, respectively. In addition, minor bleeding was occasionally observed during the procedure, 
but all bleeding episodes resolved without interventions and none led to hypotension or blood 
transfusion. 
 
4. CMV antigenemia, DNAemia, and mRNAemia in lung and heart transplant recipients (III) 
 
CMV antigenemia, DNAemia, and mRNAemia were detected in 21/21 (100 %), 20/21 (95 %), and 
13/21 (62 %) of the thoracic organ transplant recipients, respectively. A total of 46 CMV infections, 
defined as a positive result in any of the tests, occurred in the study population. CMV infection was 
detected by the antigenemia, DNAemia, and mRNAemia tests in 45/46 (98 %), 33/46 (72 %), and 
20/46 (43 %) of the cases, respectively. All the PCR positive infections were also detected by the 
antigenemia test, while CMV DNAemia was not detected in 12 (27 %) of the CMV antigenemias. 
However, all the antigenemias without concomitant DNAemia manifested as a low level of pp65-
positive leukocytes (≤ 5/50 000) and only two of these episodes required antiviral therapy. A 
significant correlation between the number of CMV pp65-positive leukocytes and the CMV 
DNAemia level was found (r = 0.69, p < 0.0001).  
 
5. Usefulness of CMV DNAemia and mRNAemia tests in guiding antiviral therapy (III) 
 
CMV DNAemia was detected in 26/28 (93 %) and mRNAemia in 17/28 (61 %) of the CMV 
antigenemias requiring antiviral therapy (p = 0.01). The two PCR negative CMV antigenemias 
treated with antiviral agents manifested as a low peak antigenemia level of 2 and 5 pp65-positive 
leukocytes, respectively. Furthermore, CMV DNAemia was detected before or at the initiation of 
the therapy in all of the 26 PCR positive CMV antigenemias. Sensitivity, specificity, and positive 
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predictive values (PPV) of the different DNAemia levels and NASBA results using the antigenemia 
test as the reference standard are presented in Table 9.  
 
Table 9. Sensitivity, specificity, and positive predictive values (PPV) of the different DNAemia 
levels (PCR) and mRNAemia (NASBA) test results using the antigenemia test as the reference. 
Blood samples collected during antiviral therapy were excluded. 
 
   
    a 
Optimal DNAemia levels from the receiver operating characteristic (ROC) curves were chosen as the 
       point nearest to the left top corner in order to achieve the maximal sum of sensitivity and specificity. 
       CMV, Cytomegalovirus.  





 Threshold levels of CMV antigenemia  
 ≥ 2 pp65-positive 
leukocytes 
≥ 5 pp65-positive 
leukocytes 
≥ 10 pp65-positive  
leukocytes 
 
Threshold levels of DNAemia (PCR)  
    
  > 400 copies/ml  
          Sensitivity (%) 75.9 91.3 100 
          Specificity (%) 92.7 87.2 85.7 
          PPV (%) 66.1 33.9 24.2 
    
  > 1000 copies/ml    
    
          Sensitivity (%) 61.1 87.0 100 
          Specificity (%) 95.5 91.9 90.5 
          PPV (%) 71.7 43.5 32.6 
    
  > 5000 copies/ml    
    
          Sensitivity (%) 24.1 47.8 66.7 
          Specificity (%) 100 99.4 99.1 
          PPV (%) 100 84.6 76.9 
    
    
Optimal DNAemia levela  400 copies/ml 850 copies/ml 1250 copies/ml 
   
          Sensitivity (%) 75.9 91.3 100 
          Specificity (%) 92.7 91.3 91.5 
          PPV (%) 66.1 42.9 34.9 
    
    
mRNAemia (NASBA)    
   
          Sensitivity (%) 25.9 43.5 56.3 
          Specificity (%) 99.6 98.4 98.1 
          PPV (%) 93.3 66.7 60.0 
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6. HHV-6 and HHV-7 activation in lung transplant recipients (IV) 
 
During the first posttransplant year HHV-6, HHV-7, and CMV antigenemia were detected in 20/22 
(91 %), 11/22 (50 %), and 12/22 (55 %) of the LTRs, respectively. After Tx, HHV-6 antigenemia 
first appeared in a median of 16 (range 9 - 232) days, HHV-7 antigenemia in a median of 31 (range 
1 - 198) days, and CMV antigenemia in a median of 165 (range 94 - 323) days. The cumulative 












Figure 8. Log-rank curves showing the timing of the first detection of HHV-6, HHV-7, and CMV 
antigenemia in 22 lung transplant recipients. HHV-6 vs. CMV (p < 0.001) and HHV-6 vs. HHV-7 (p 
< 0.01). Ganciclovir or valganciclovir prophylaxis was given to 19/22 (86 %) of the patients (IV). 
HHV 6, Human herpesvirus 6; HHV 7, Human herpesvirus 7; CMV, Cytomegalovirus. 
Reprinted from the orginal publication (IV) with the permission from the publisher (Elsevier and ISHLT). 
 
 
HHV-6, HHV-7, and CMV antigens were detected in 170/324 (52.5 %), 57/324 (17.6 %), and 
42/324 (13.0 %) of the blood specimens and in 8/181 (4.4 %), 1/181 (0.6 %), and 3/181 (1.7 %) of 
the BALF samples, respectively. Seven out of the nine BALF samples showing HHV-6 or HHV-7 
antigens were microscopically blood-contaminated, and in eight cases HHV-6 or HHV-7 was 
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detected concomitantly in the blood and BALF. HHV-6 was detected concomitantly in 12/18 (67 
%) and HHV-7 in 6/18 (33 %) of the episodes of CMV antigenemia. 
 
One case of mild pneumonitis was possibly caused by HHV-6 and another recipient had 
encephalitis associated with the appearance of HHV-6 antigenemia.  Neither of these recipients 
received CMV prophylaxis (R-/D-). All the other episodes of the HHV-6 or HHV-7 antigenemias 
were either asymptomatic or the possible manifestations could not be distinguished from those of 
the concomitant infections (e.g. CMV), drug side-effects or complications of the immediate 
postoperative period. 
 
7. Efficacy of the antiviral prophylaxis against CMV, HHV-6, and HHV-7 antigenemia  
(III, IV) 
 
In the Study III, the first detection of CMV antigenemia was delayed in the patients receiving CMV 
prophylaxis (median of 137 days) when compared to the recipients without the prophylaxis (median 
of 23 days).  
 
The incidences of HHV-6, HHV-7, and CMV antigenemia in 19 recipients receiving ganciclovir or 
valganciclovir as antiviral prophylaxis against CMV in the Study IV are shown in Table 10. 
Induction therapy with ATG was given to all five recipients with ganciclovir prophylaxis, but only 
to one patient with valganciclovir prophylaxis. All three CMV-seronegative recipients having a 
graft from a seronegative donor (R-/D-) developed HHV-6 antigenemia and two HHV-7 
antigenemia during the acyclovir prophylaxis, but none suffered from a primary CMV infection. 
The concomitant HHV-6 and HHV-7 antigenemia responded to the antiviral therapy directed 
against CMV in terms of disappearance of the virus from blood in 9/12 (75 %) and 5/6 (83 %) of 
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the cases, respectively. However, the efficacy of the therapy against HHV-6 and HHV-7 was often 
delayed and less clear when compared to that of CMV antigenemia. 
 
 
Table 10. The incidences of HHV-6, HHV-7, and CMV antigenemia in lung transplant recipients 
with antiviral prophylaxis against CMV. 
                            
 
    
 
Total (n = 19) GAN (n = 5) ValGAN (n = 14) P-value a 
     
  Breakthrough antigenemia  
  during prophylaxis     
            HHV-6 15/19 (79 %)  4/5 (80 %) b 11/14 (79 %) p > 0.05 
            HHV-7  7/19 (37 %)  4/5 (80 %) b   3/14 (21 %) p = 0.04 
            CMV 1/19 (7 %)     0/5 (0 %) 1/14 (7 %) p > 0.05 
     
  Total incidence of antigenemia     
            HHV-6  17/19 (89 %)  5/5 (100 %)  12/14 (86 %) p > 0.05 
            HHV-7    9/19 (47 %)  5/5 (100 %)    4/14 (29 %) p = 0.01 
            CMV  12/19 (63 %)  5/5 (100 %)    7/14 (50 %) p > 0.05 
     
                  
           HHV 6, Human herpesvirus 6; HHV 7, Human herpesvirus 7; CMV, Cytomegalovirus; GAN, ganciclovir; 
          valGAN, valganciclovir 
           a GAN vs. valGAN prophylaxis                   
                b Three HHV-6 and HHV-7antigenemias appeared during p.o. and one during i.v. ganciclovir 


















1. Usefulness of bronchoscopy 
 
 The diagnostic yield of BAL has varied largely, from 27 to 69 %, in immunocompromised hosts 
including SOT recipients (Cazzadori et al. 1995, Torres et al. 2000, Rano et al. 2001, Reichenberger 
et al. 2001, Jain et al. 2004). In the only report evaluating the use of bronchoscopy solely in HTRs 
(Schulman et al. 1998) the diagnostic yield was somewhat higher (62 %) than that found in the 
present study (41 %). Two factors, probably increasing the diagnostic yield in the Schulman study, 
were the frequently performed TBBs and the absence of Pneumocystis prophylaxis (Schulman et al. 
1988). Clinically indicated bronchoscopies performed on the LTRs revealed a specific diagnosis in 
61 % of the cases in the present study, the majority of the diagnoses being respiratory infections. 
The higher diagnostic yield of bronchoscopy in the LTRs compared to that in the HTRs can be 
explained by the high frequency of infections as well as by other postoperative complications (e.g. 
rejection) in the lung allograft. The diagnostic yield of clinically indicated bronchoscopy in the 
present study is in line with that of previous reports on LTRs (Chan et al. 1996, Baz et al. 1996). 
The utility of bronchoscopy was highest from one to six months after Tx in both the HTRs and 
LTRs. This is suggested to be mainly due to the high occurrence of opportunistic respiratory 
infections as well as to acute rejections (LTRs) during this time interval. 
  
There are two general issues which have to be addressed to when the usefulness of bronchoscopy in 
the diagnosis of a suspected respiratory infection is evaluated. Firstly, the sensitivity or specificity 
of bronchoscopy is difficult to determine due to the lack of “the gold standard” for the diagnosis of 
pneumonia. Nevertheless, although the widely used term “diagnostic yield” (the proportion of the 
procedures by which a specific diagnosis is achieved) is not equal to sensitivity, it provides valuable 
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information of the usefulness of bronchoscopy in different clinical settings.  Secondly, as 
approximately half of the SOT recipients with a suspected respiratory infection may not receive the 
diagnosis through bronchoscopy, its role as recommended diagnostic procedure could be 
questioned. However, the usefulness of bronchoscopy has to be weighted against the low yield of 
non-invasive procedures (e.g. blood cultures or sputum analysis) and the risks of performing open 
lung biopsy in immunocompromised patients (Nusair and Kramer 1999, Chang et al. 2004, Shorr et 
al. 2004). Thus, bronchoscopy is a valuable procedure for the diagnosis of respiratory infections in 
transplant recipients compared to other available diagnostic methods. 
 
More than half of the Tx centres perform regularly scheduled surveillance bronchoscopies on 
asymptomatic LTRs in order to detect clinically silent rejection or infection (Kukafka et al. 1997). 
Only 15 % of the surveillance bronchoscopies established a specific diagnosis in the present 
material, which is a slightly lower yield than that received in most previous reports (Baz et al. 1996, 
Hopkins et al. 2002, Chakinala et al. 2004). It can be explained by two factors. Firstly, the 
occurrence of acute rejection was low in the present material with none of the surveillance TBBs 
establishing grade ≥ 2 acute rejection. This reflects a relatively high net state immunosuppression of 
the LTRs in the Study II (all patients received ATG). Secondly, the routine surveillance of the LTRs 
by chest CT scan led to rather strict criteria for surveillance bronchoscopies: the procedures were 
classified as clinically indicated when changes were detected in the CT scan even in asymptomatic 
recipients with clear plain chest radiography. Nevertheless, since the surveillance bronchoscopies 
seldom changed the medical therapy of the patient, the present author agrees with some of the 
previous studies questioning the role of surveillance bronchoscopies in the management of LTRs 




All the major complications of the bronchoscopy in the HTRs were cardiovascular and occurred in 
patients with a compromised cardiovascular condition. According to international 
recommendations, bronchoscopy should be avoided in patients with poorly controlled congestive 
heart failure or a history of recent myocardial infarction (Honeybourne et al. 2001). This 
recommendation is difficult to follow in HTRs. In LTRs, the complication rate of bronchoscopy in 
the present study (2.1 %) was lower than that in most previous studies, but similar to the rate (2.0 
%) reported by Dransfield and co-workers (Baz et al.1996, Boehler et al. 1996, Hopkins et al. 2002, 
Dransfield et al. 2004). In the present study, the bleeding volume was not routinely calculated after 
a minor bleeding. In addition, TBBs were taken in only 32 % of the bronchoscopies performed on 
the LTRs. These factors probably lower the present complication rate compared to that of previous 
reports. 
 
2. Significance of microbes retrieved by bronchoscopy 
 
Pneumocystis carinii was a frequently detected pathogen in the BALF in the present study. This 
finding is expectable in patients who underwent HTx before the institution of chemoprophylaxis. 
However, the relatively high frequency of P. carinii in the LTRs who were receiving the 
prophylaxis is surprising, since Co-trimoxazole and inhaled pentamidine are highly effective in 
preventing PCP (Schneider 1992, Nathan et al. 1994, Gordon et al. 1999).  P. carinii was detected 
by surveillance bronchoscopy in five cases, while all the other LTRs with P.carinii demonstrated in 
the BALF or TBBs had respiratory symptoms and/or radiographic infiltrates. Thus, although some 
of the cases may have represented the result of airborne transmission of the organism or 
colonization of the recipient, it is likely that most of the recipients had a clinical infection. 
Significant mortality rates of about 30 - 40 % in PCP have been reported in patients without 
prophylaxis (Gordon et al. 1999, Roblot et al. 2002). In contrast, all patients in the present study 
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responded to the therapy, suggesting that previous chemoprophylaxis may modify the clinical 
picture of PCP. The optimal length of the prophylaxis against P. carinii in SOT recipients remains a 
matter of debate (Fishman and Rubin 1998, Gordon et al. 1999, Villician and Paya 1999). In the 
present patients, P. carinii was detected in the LTRs from the immediate postoperative period to 
more than two years post-transplantation, and two HTRs suffered from PCP soon after 
discontinuation of the Co-trimoxazole prophylaxis. Thus it is reasonable to give lifelong P. carinii 
prophylaxis for LTRs, as stated by Gordon and co-workers (Gordon et al. 1999). Nevertheless, 
P.carinii infections still occur in LTRs despite the chemoprophylaxis, and bronchoscopy is 
warranted in the diagnosis and surveillance of this organism. The present results also support the 
recommendations to expand the length of the prophylaxis beyond six months in HTRs, especially 
when the level of immunosuppression is intensified (Villician and Paya 1999, Fishman 2001). 
 
Detecting CMV by the antigen test or culture in the BALF had a poor positive predictive value in 
the LTRs, when rather strict criteria were used for the diagnosis of CMV pneumonia. Similarly, a 
limited impact of CMV culture or antigen detection from the BALF on medical treatment has been 
detected in bone marrow transplant recipients (Ruutu et al. 1990, Feinstein et al. 2001). However, in 
two recent studies the quantitative measurements of CMV DNA from BALF are suggested to be 
more predictive of CMV pneumonia than the screening of CMV DNAemia from blood on the LTRs 
(Westall et al. 2004, Chemaly et al. 2005). This method could serve as a good alternative in the 
demonstration of CMV in BALF. 
 
In the present study, bacteria were the most common causative agents for respiratory infection in 
the LTRs. Pseudomonas aeruginosa and Staphylococcus aureus were the most common bacteria, 
which is in line with the international reports (Trulock 1999). In contrast, the diagnostic accuracy of 
the present bronchoscopic samples for bacterial pneumonia was low in the HTRs. The most likely 
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reason for this is the empiric antibiotic therapy which was widely used at the time of the 
bronchoscopy. Furthermore, the use of quantitative cultures could have increased the diagnostic 
yield of the bronchoscopy by detecting the high growth of bacteria which was interpreted as 
colonization the present study.    
 
Aspergillus airway colonization is regarded as a risk factor for anastomotic complications as well as 
for an invasive disease in LTRs (Nathan et al. 2000, Cahill et al. 1997). The present results could 
not show any clear association between aspergillus colonization and anastomotic complications in 
the LTRs. This can be partly explained by the low number of patients in the present study and by 
the use of the pre-emptive antifungal therapy in some of the patients by the discretion of the 
physician.  
 
3. CMV DNAemia and mRNAemia and their relationship to antigenemia 
 
The antigenemia and DNAemia (PCR) tests proved to be more sensitive in detecting CMV infection 
than the mRNAemia (NASBA) assay in the present study. The inability of NASBA to guide the 
antiviral therapy was demonstrated by two factors. Firstly, 39 % of the CMV antigenemia episodes 
requiring antiviral therapy were not detected by NASBA. Secondly, the sensitivity of the assay was 
low (25.9 - 56.3 %) in detecting the CMV antigenemia level of 2-10 pp65-positive leukocytes.  In 
contrast to the present results, Gerna and coworkers concluded in their study that the antigenemia 
test could be replaced by NASBA in the guidance of the pre-emptive therapy in thoracic organ 
transplant recipients. However, a higher threshold level for the initiation of the therapy (100 pp65-





The CMV DNAemia levels measured by The Cobas Amplicor PCR assay showed a good overall 
correlation with the pp65-antigenemia test results in the present material, which is in line with 
previous reports on SOT recipients (Caliendo et al. 2002, Pang et al. 2003). In order to evaluate the 
clinical usefulness of this correlation, the ROC curve analysis was performed to estimate the cut-off 
levels for CMV DNAemia corresponding to the antigenemia levels used for the initiation of the pre-
emptive therapy. The optimal cut-off levels of CMV DNAemia to achieve maximal combined 
sensitivity and specificity were 850 and 1250 copies/ml for the antigenemia levels of 5 and 10 
pp65-positive leukocytes, respectively. The sensitivities and specificities with these DNAemia 
tresholds were over 90 %, but the PPVs were low. Thus, using the above-mentioned cut-off levels 
for the initiation of the pre-emptive therapy all of the CMV antigenemias over 10 pp65-positive 
leukocytes and a great majority of antigenemias over 5 pp65-positive leukocytes would be treated, 
but if the antiviral therapy is initiated with DNAemia levels from ca. 1000 to 5000 copies/ml, some 
of the CMV infections might actually represent an antigenemia under 5-10 pp65-positive 
leukocytes. The sensitivity of any positive PCR result for an antigenemia level of 2 or more pp65-
positive leukocytes was 75.9 %. If this lowest antigenemia level is used for the initiation of the pre-
emptive therapy, the best alternative to the pp65-antigenemia test might be one of the real-time PCR 
assays, which, in the previous studies, has been even more sensitive than the Cobas Amplicor PCR 
test and the antigenemia assay (Pang et al. 2003, Piiparinen et al. 2004, Herrmann et al. 2004).  
 
Although the antigenemia test was slightly more sensitive than the PCR assay in the present study, 
the differences between these two assays were not considered to be of major clinical significance. 
All the PCR-negative CMV infections manifested as low-level antigenemia; only two of the CMV 
infections requiring antiviral therapy were PCR-negative, and DNAemia was present until the 
initiation of the therapy in all the PCR-positive cases. Furthermore, the antigenemia test was 
arbitrarily selected for the reference assay, because it was traditionally used to demonstrate CMV 
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infection and guide pre-emptive therapy.  It has to be noted, however, that the absolute superiority 
of the antigenemia, DNAemia or even mRNAemia assay over each other in detecting clinically 
significant CMV infection falls beyond the scope of the present study. 
 
There are some limitations in the Study III. Firstly, there were differences in the prevention and 
treatment of the CMV infections between the HTRs and LTRs (prophylaxis and thresholds for pre-
emptive therapy). This may weaken the clinical relevance of the conclusions made, when 
considered for each transplant group separately. However, the two other CMV assays could be 
compared to the antigenemia test in general by calculating the sensitivities and specificities for the 
different cut-off levels of antigenemia. Secondly, some of the blood samples could not be retrieved 
to the laboratory in time to be valid for the CMV assays. Long geographical distances are 
considered one of the major problems in collecting samples for the CMV tests and applying the pre-
emptive treatment strategy (Singh 2001, Zamora 2004a). Thus, CMV tests that could be reliably 
performed also in distant centres (e.g. based on commercially available PCR) are needed.  
 
4. HHV-6 and HHV-7 antigenemia in lung transplant recipients 
 
In the present study a high incidence of HHV-6 antigenemia (91 %) and a lower incidence of HHV-
7 antigenemia (50 %) were found after LTx during the first posttransplant year. In previous studies 
on SOT recipients the HHV-6 occurred in 0 - 66 % and HHV-7 in 42 - 89 % of the patients 
(Griffiths et al. 1999, Brennan et al. 2000, Lautenschlager et al. 2000, Des Jardin et al. 2001, 
Mendez et al. 2001, Michaelides et al. 2002, Jacobs et al. 2003, Razonable et al. 2005). Similarly to 
the present study, activation of both viruses has usually been detected during the first postoperative 
month after Tx (Brennan et al. 2000, Humar et al. 2002, Jacobs et al. 2003). There are two main 
reasons for the wide variation in the incidences reported. Firstly, the organ transplanted influences 
67
 
the risk of viral infection through the differences in the immunosuppressive therapy. Secondly, the 
diagnostic method differs between the studies. However, the HHV-6 activation was detected in the 
present study more frequently than in previous studies on SOT recipients. It was shown in a recent 
study that HHV-6 antigenemia and DNAemia correlate well in liver transplant recipients (Härmä et 
al. 2005). Thus it is suggested that the relatively high incidence of HHV-6 in the present study is 
not entirely related to the method used. The relatively high occurrence of CMV antigenemia and the 
possible higher net-state immunosuppression, at least when compared to other SOT recipients than 
LTRs, may have influenced the high incidence of HHV-6 in the present patients. In a few reports of 
HHV-7 in SOT recipients, the incidence of the virus has been comparable to that of the present 
study (Griffiths et al. 1999, Mendez et al. 2001, Razonable et al. 2005). HHV-6 and, to a lesser 
extent, HHV-7 were frequently detected concomitantly or preceding the CMV antigenemia. This is 
in concordance with previous studies and suggests interactions between the viruses (Des Jardin et 
al. 2001, Lautenschlager et al. 2002, Razonable et al. 2003). 
 
In the present study it was not possible to confirm any symptoms or findings to be solely due to 
HHV-6 or HHV-7. The manifestations of the viral activations were either asymptomatic or difficult 
to differentiate from those of other posttransplant complications (e.g. CMV or other infections). 
However, one case of mild pneumonitis was possibly caused by HHV-6, and another recipient had 
encephalitis associated with HHV-6 antigenemia.  Neither of these recipients received CMV 
prophylaxis. Although most of the HHV-6 and HHV-7 activations have been asymptomatic also in 
other studies, the possibility that antiviral prophylaxis modifies the clinical picture of HHV-6 or 
HHV-7 infection cannot be ruled out (Emery 2001, Humar et al. 2002, Jacobs et al. 2003). 
 
Compared to the present results, higher occurrence of HHV-6 and HHV-7 in the BALF have been 
reported in other studies (Ross et al. 2001, Jacobs et al. 2003, Neurohr et al. 2005). In the present 
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study microscopic blood contamination was often present in the BALF samples with HHV-6 or 
HHV-7 antigen positive cells. Previous studies have used PCR-based methods, and the proportion 
of BALF samples with microscopic blood contamination has not been reported. As in the present 
study, the detection of HHV-6 or -7 in the BALF has only seldom been associated with clinical 
pneumonitis in the previous studies (Jacobs et al. 2003). Thus it is suggested that most of the 
positive findings of these viruses from the BALF may actually represent the concomitant 
antigenemia or DNAemia. 
 
5. Antiviral strategies against CMV, HHV-6, and HHV-7 
 
Since high morbidity and mortality are related to CMV after LTx, antiviral prophylaxis against the 
virus is widely recommended (Zamora et al. 2005). Therefore, the majority of the LTRs in the 
Studies III and IV received antiviral prophylaxis (excluding those with a R-/D- match), and, 
consequently, comparison between the LTRs with and those without prophylaxis was not possible. 
However, two conclusions regarding the prophylaxis may be drawn from the present results: 
 (i) Intravenous/oral ganciclovir or oral valganciclovir prophylaxis delayed CMV infection when 
compared to the HTRs without prophylaxis, but CMV infection developed soon after the cessation 
of the prophylaxis in the Study III. The fact that short-term (≤ 3 months) antiviral prophylaxis 
delays rather than prevents CMV infection is in concordance with previous studies (Duncan et al. 
1994, Soghikian et al. 1996, Humar et al. 2005). This raises a question about the reasonable length 
of antiviral prophylaxis. After the Study III, the length of the CMV prophylaxis in the LTRs was 
expanded up to 6-9 months at Helsinki University Central Hospital as can be seen in the Study IV. 
It is also to be noted that the incidence of CMV antigenemia was 50 % in LTRs with valganciclovir 
prophylaxis (median of six months), while all of the five patients (100 %) with ganciclovir 
prophylaxis for three months developed CMV infection. The difference was not statistically 
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significant, and the change in the induction therapy may act as confounding factor. Nevertheless, 
the present results are in concordance with the study by Zamora et al. who showed that the use of 
valganciclovir prophylaxis for a minimum of 180 POD decreases the occurrence of CMV infection 
when compared to a shorter duration of prophylaxis (Zamora et al. 2004b). 
 (ii) Antiviral prophylaxis could not prevent the appearance of HHV-6 or -7 antigenemia. HHV-6, 
unlike CMV, appeared frequently even during the prophylaxis. Razonable and coworkers found a 
lower incidence of HHV-6DNAemia and a similar incidence of HHV-7DNAemia compared to the 
historical data in SOT recipients (no LTRs included) receiving CMV prophylaxis (Razonable et al. 
2005). A considerable proportion of LTRs (50 %) developed HHV-6DNAemia despite ganciclovir 
prophylaxis in the study by Jacobs et al., but the incidence was even higher (91 %) among the 
patients without prophylaxis (Jacobs et al. 2003). Similarly to the studies on the incidence of HHV-
6 and HHV-7, the variability in the immunosuppressive medications and virological methods is 
probably the main reason for the differences between the studies assessing the efficacy of antiviral 
prophylaxis. Nevertheless, the higher susceptibility of CMV to ganciclovir compared to HHV-6 and 
HHV-7 in vitro gives evidence of the different efficacy of the antiviral prophylaxis against the three 
beta-herpesviruses (De Clercq et al. 2001). In the present study, HHV-7 antigenemia was more 
common in the patients receiving ganciclovir than valganciclovir prophylaxis, but the change in the 
use of the ATG induction therapy may explain the difference. 
 
Pre-emptive treatment strategy guided by the CMV antigenemia assay was used in both present 
prospective studies (III and IV). The actual rationale of the pre-emptive strategy and the usefulness 
of the different CMV assays evaluated in the Study III depend on whether low-level antigenemia is 
considered significant and warrants the therapy. A wide variation of the cut-off levels for the 
initiation of the pre-emptive therapy exists between transplant centres and clinical studies (van der 
Bij and Speich 2001, Vilchez et al. 2001, Kelly et al. 2000, Limaye et al. 2002). Relevant thresholds 
70
 
are recommended to be validated for clinical practice at each centre (Zamora et al. 2005). In the 
Study III, there were 17 episodes of spontaneously resolving low-level antigenemia of which 
DNAemia and mRNAemia were present in only 41 and 12 % of the cases, respectively. It could be 
argued that using the antigenemia test in the surveillance of CMV with low thresholds for the pre-
emptive therapy might lead to unnecessary controls and too aggressive treatment of CMV 
antigenemia increasing the costs of the pre-emptive treatment strategy, the incidence of the side-
effects of antiviral drugs, and the risk for drug resistance of CMV. On the other hand, with no 
effective treatment available, attention has been focused on the prevention of potential risk factors 
for the development of BOS and CAV. Some of the recent reports suggest that even asymptomatic 
CMV antigenemia or DNAemia could lead to chronic allograft injury, which may justify early 
therapeutic intervention (Potena et al. 2003, Westall et al. 2003, Potena et al. 2006). HHV-6 and 
HHV-7 antigenemia commonly subsided with the treatment directed against CMV, though the 
response was somewhat unclear. Nevertheless, the therapeutic dosing of the drugs used to treat 
established CMV infection may be the main cause why the antiviral therapy seems to be more 
effective than the prophylaxis against HHV-6 and HHV-7. 
 
The prevention and treatment of CMV infection, possibly together with other beta-herpesviruses, 
may be of importance, not only in controlling the clinical viral disease, but also in restricting the 
occurrence of chronic allograft injury in thoracic organ transplant recipients. Whether blocking all 
CMV replication (low-level antigenemia or DNAemia) or inhibiting HHV-6 or HHV-7 activation 
can prevent these major complications and improve the long-term survival of the recipients, remains 
still an unanswered question. Future prospective studies are needed to evaluate the optimal 
indications for the initiation of the pre-emptive therapy and the overall efficacy of preventive 
antiviral strategies on CMV, HHV-6, and HHV-7, taking into account both the direct and indirect 





Bronchoscopy with BAL, PSB and TBB (LTRs) is a useful and safe diagnostic tool in thoracic 
organ transplant recipients, when respiratory infection is suspected. Its utility is best at one to six 
months after Tx when the variability of the microbial aetiology is largest. 
 
The rationale of performing surveillance bronchoscopies on LTRs remains controversial. The 
surveillance TBBs, in particular, yield only little clinically significant information to support their 
performance. 
 
P.carinii infections occur in LTRs despite the chemoprophylaxis and in HTRs after discontinuation 
of the prophylaxis. This justifies the use of bronchoscopy to detect this organism in thoracic organ 
transplant recipients, even in the era of chemoprophylaxis.  
 
In thoracic organ transplant recipients, CMV DNAemia assay is comparable with the pp65-
antigenemia test in guiding the pre-emptive therapy against CMV infections, when threshold levels 
of over 5 pp65-antigen positive leukocytes/50 000 PMNLs are used as reference. The mRNAemia 
test is less sensitive than the pp65-antigenemia or the DNAemia test in HTRs and LTRs. This limits 
its usefulness in the guidance of the pre-emptive therapy. 
 
HHV-6 and HHV-7 antigenemia is common and appears early after LTx. Clinical manifestations 
are infrequently linked solely to HHV-6 or HHV-7. Antiviral prophylaxis against CMV is not able 





YHTEENVETO (FINNISH SUMMARY) 
 
Elinsiirto tarjoaa loppuvaiheen keuhko- ja sydänsairauksista kärsiville potilaille ennustetta ja 
elämänlaatua parantavan hoitomahdollisuuden. Keuhkon- ja sydämensiirtopotilaiden hoidossa 
infektiot ovat merkittävä ongelma yleisyytensä sekä niihin liittyvän korkean kuolleisuuden vuoksi. 
Elinsiirtopotilailla infektioiden aiheuttajakirjo on laaja ja poikkeaa normaaliväestön vastaavasta 
kirjosta. Sen vuoksi käyttökelpoiset menetelmät infektioiden diagnostiikassa ovat välttämättömiä. 
Tässä tutkimuksessa selvitettiin bronkoskopian käyttökelpoisuutta keuhkon- ja 
sydämensiirtopotilaiden infektiodiagnostiikassa, verrattiin sytomegalovirus(CMV)-infektioiden 
osoittamiseen käytettäviä menetelmiä näillä potilailla sekä ihmisen herpesvirusten 6 ja 7 (HHV-6 ja 
HHV-7) esiintymistä ja merkitystä keuhkonsiirtopotilailla. 
 
Tutkimme kaikkien toukokuusta 1988 joulukuuhun 2001 sydämensiirtopotilaille ja helmikuusta 
1994 marraskuuhun 2002 keuhkonsiirtopotilaille tehtyjen bronkoskopioiden tulokset. 
Infektioepäilyn yhteydessä spesifinen diagnoosi saatiin 41 %:lle sydämensiirtopotilaista ja 61 %:lle 
keuhkonsiirtopotilaista tehtyjen bronkoskopioiden näytteistä. Bronkoskopia osoittautui 
hyödyllisimmäksi ajanjaksona yhdestä kuuteen kuukautta elinsiirron jälkeen. Sen sijaan 
oireettomille keuhkonsiirtopotilaille tehdyt ns. seuranta bronkoskopiat toivat harvoin 
merkityksellisiä löydöksiä, ja hoitoa muutettiin näiden tutkimusten perusteella vain 6 %:ssa 
tapauksista. Bronkoskopia todettiin varsin turvalliseksi toimenpiteeksi, vaikkakin muutamia 
vakavia komplikaatioita esiintyi. Pneumocystis carinii ja CMV olivat yleisimmät 
bronkoskopianäytteissä todetut mikrobit molemmissa potilasryhmissä. Yllättävänä löydöksenä 





Seurasimme 17.12.2000 - 15.4.2003 keuhkon- tai sydämensiirron saaneita potilaita verestä 
tehtävien CMV-antigenemia-, DNAemia- (Cobas Amplicor PCR) ja mRNAemia (NASBA)- testien 
avulla. CMV-infektiot hoidettiin antigenemiatestin tulosten perusteella, ja kahden muun CMV-
testin tuloksia verrattiin antigenemiatestiin. DNAemia-testi oli positiivinen 93 %:lla kaikista 
lääkehoitoa vaatineista CMV antigenemioista, mutta mRNAemia todettiin vain 61 %:ssa näistä 
infektioista. Antigenemia- ja DNAemia-testien tulokset korreloivat hyvin aineistossamme. 
Antigenemiatasoja 2, 5 ja 10 pp65-positiivista leukosyyttiä/50 000 leukosyyttiä vastaavat 
maksimaalisen sensitivisyyden ja spesifisyyden summan tuottavat DNAemia (sens./spes.)-tasot 
olivat 400 (75.9 % / 92.7 %), 850 (91.3 % / 91.3 %) ja 1250 (100 % / 91.5 %) kopiota/ml. Edellä 
mainittuja antigenemiatasoja vastaavat mRNAemia-testin sensitivisyydet olivat vain 25.9 %, 43.5 
% ja 56.3 %. 
 
Ajanjaksona 17.12.2000 - 06.10.2004 keuhkonsiirron saaneita potilaita seurattiin CMV-
antigenemiatestin lisäksi myös HHV-6:n ja HHV-7:n suhteen valkosolujen antigeenitestien avulla. 
Keuhkonsiirtopotilaista 91 %:lla todettiin HHV-6 antigenemia ja 50 %:lla HHV-7 antigenemia. 
Molemmat virukset aktivoituivat yleensä ensimmäisen postoperatiivisten kuukauden aikana. 
Yhdellä potilaalla HHV-6 viruksen aktivaatio assosioitui radiologisiin keuhkomuutoksiin ja toisella 
potilaalla neurologisiin löydöksiin, mutta suurimpaan osaan HHV-6 ja HHV-7 antigenemioista ei 
voitu liittää selkeitä oireita. Gansikloviiri tai valgansikloviiri estolääkityksen aikana 15 potilaalla 
(79 %) todettiin HHV-6 ja seitsemällä (37 %) HHV-7 antigenemia, mutta vain yhdellä potilaalla 
CMV antigenemia. 
 
Tutkimuksemme perusteella bronkoskopia on turvallinen ja käyttökelpoinen menetelmä keuhkon- 
ja sydämensiirtopotilaiden keuhkoinfektioiden diagnostiikassa. Sen sijaan oireettomille 
keuhkonsiirtopotilaille tehtävien seuranta-bronkoskopioiden hyödyllisyys on kyseenalainen. 
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Bronkoskopiaa tarvitaan edelleen P.carinii infektioiden osoittamisessa. CMV DNAemia-testi 
(Cobas Amplicor PCR) vaikuttaa toimivan yhtä hyvin CMV infektioiden hoidon ohjannassa 
verrattuna CMV antigenemiatestiin, kun hoidon aloittamisen kynnysarvoina on käytetty yli 5 pp65-
positiiivista leukosyyttiä. Sitä vastoin NASBA-testin matala sensitiivisyys rajoittaa sen käyttöä pre-
emptiivisen hoidon ohjannassa. HHV-6 ja HHV-7 antigenemia on yleistä keuhkonsiirron jälkeen, 
eikä CMV infektioita vastaan suunnattu estolääkitys kykene estämään niitä. Näiden virusten 
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